292,510 results on '"randomized controlled trials as topic"'
Search Results
2. Best Case/Worst Case-ICU: protocol for a multisite, stepped-wedge, randomised clinical trial of scenario planning to improve communication in the ICU in US trauma centres for older adults with serious injury.
- Author
-
Stalter, Lily, Hanlon, Bret, Bushaw, Kyle, Kwekkeboom, Kristine, Zelenski, Amy, Fritz, Melanie, Buffington, Anne, Stein, Deborah, Cocanour, Christine, Robles, Anamaria, Jansen, Jan, Brasel, Karen, OConnell, Kathleen, Cipolle, Mark, Ayoung-Chee, Patricia, Morris, Rachel, Gelbard, Rondi, Kozar, Rosemary, Lueckel, Stephanie, and Schwarze, Margaret
- Subjects
adult intensive & critical care ,clinical trial ,medical ethics ,palliative care ,trauma management ,Aged ,Female ,Humans ,Male ,Middle Aged ,Communication ,Family ,Intensive Care Units ,Randomized Controlled Trials as Topic ,Trauma Centers ,United States ,Wounds and Injuries ,Multicenter Studies as Topic - Abstract
INTRODUCTION: Poor communication about serious injury in older adults can lead to treatment that is inconsistent with patient preferences, create conflict and strain healthcare resources. We developed a communication intervention called Best Case/Worst Case-intensive care unit (ICU) that uses daily scenario planning, that is, a narrative description of plausible futures, to support prognostication and facilitate dialogue among patients, their families and the trauma ICU team. This article describes a protocol for a multisite, randomised, stepped-wedge study to test the effectiveness of the intervention on the quality of communication (QOC) in the ICU. METHODS AND ANALYSIS: We will follow all patients aged 50 and older admitted to the trauma ICU for 3 or more days after a serious injury at eight high-volume level 1 trauma centres. We aim to survey one family or like family member per eligible patient 5-7 days following their loved ones admission and clinicians providing care in the trauma ICU. Using a stepped-wedge design, we will use permuted block randomisation to assign the timing for each site to begin implementation of the intervention and routine use of the Best Case/Worst Case-ICU tool. We will use a linear mixed-effects model to test the effect of the tool on family-reported QOC (using the QOC scale) as compared with usual care. Secondary outcomes include the effect of the tool on reducing clinician moral distress (using the Measure of Moral Distress for Healthcare Professionals scale) and patients length of stay in the ICU. ETHICS AND DISSEMINATION: Institutional review board (IRB) approval was granted at the University of Wisconsin, and all study sites ceded review to the primary IRB. We plan to report results in peer-reviewed publications and national meetings. TRIAL REGISTRATION NUMBER: NCT05780918.
- Published
- 2024
3. Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis.
- Author
-
Luijten, Dieuwke, Douillet, Delphine, Luijken, Kim, Tromeur, Cecile, Penaloza, Andrea, Hugli, Olivier, Aujesky, Drahomir, Barco, Stefano, Bledsoe, Joseph, Chang, Kyle, Couturaud, Francis, den Exter, Paul, Font, Carme, Huisman, Menno, Jimenez, David, Kabrhel, Christopher, Kline, Jeffrey, Konstantinides, Stavros, van Mens, Thijs, Otero, Remedios, Peacock, W, Sanchez, Olivier, Stubblefield, William, Valerio, Luca, Vinson, David, Wells, Philip, van Smeden, Maarten, Roy, Pierre-Marie, and Klok, Frederikus
- Subjects
Clinical decision-making ,Early discharge ,Emergency care ,Outpatient care ,Pulmonary embolism ,Humans ,Pulmonary Embolism ,Acute Disease ,Home Care Services ,Hemorrhage ,Male ,Female ,Anticoagulants ,Randomized Controlled Trials as Topic ,Prospective Studies ,Aged ,Natriuretic Peptide ,Brain ,Middle Aged - Abstract
BACKGROUND AND AIMS: Home treatment is considered safe in acute pulmonary embolism (PE) patients selected by a validated triage tool (e.g. simplified PE severity index score or Hestia rule), but there is uncertainty regarding the applicability in underrepresented subgroups. The aim was to evaluate the safety of home treatment by performing an individual patient-level data meta-analysis. METHODS: Ten prospective cohort studies or randomized controlled trials were identified in a systematic search, totalling 2694 PE patients treated at home (discharged within 24 h) and identified by a predefined triage tool. The 14- and 30-day incidences of all-cause mortality and adverse events (combined endpoint of recurrent venous thromboembolism, major bleeding, and/or all-cause mortality) were evaluated. The relative risk (RR) for 14- and 30-day mortalities and adverse events is calculated in subgroups using a random effects model. RESULTS: The 14- and 30-day mortalities were 0.11% [95% confidence interval (CI) 0.0-0.24, I2 = 0) and 0.30% (95% CI 0.09-0.51, I2 = 0). The 14- and 30-day incidences of adverse events were 0.56% (95% CI 0.28-0.84, I2 = 0) and 1.2% (95% CI 0.79-1.6, I2 = 0). Cancer was associated with increased 30-day mortality [RR 4.9; 95% prediction interval (PI) 2.7-9.1; I2 = 0]. Pre-existing cardiopulmonary disease, abnormal troponin, and abnormal (N-terminal pro-)B-type natriuretic peptide [(NT-pro)BNP] at presentation were associated with an increased incidence of 14-day adverse events [RR 3.5 (95% PI 1.5-7.9, I2 = 0), 2.5 (95% PI 1.3-4.9, I2 = 0), and 3.9 (95% PI 1.6-9.8, I2 = 0), respectively], but not mortality. At 30 days, cancer, abnormal troponin, and abnormal (NT-pro)BNP were associated with an increased incidence of adverse events [RR 2.7 (95% PI 1.4-5.2, I2 = 0), 2.9 (95% PI 1.5-5.7, I2 = 0), and 3.3 (95% PI 1.6-7.1, I2 = 0), respectively]. CONCLUSIONS: The incidence of adverse events in home-treated PE patients, selected by a validated triage tool, was very low. Patients with cancer had a three- to five-fold higher incidence of adverse events and death. Patients with increased troponin or (NT-pro)BNP had a three-fold higher risk of adverse events, driven by recurrent venous thromboembolism and bleeding.
- Published
- 2024
4. Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project.
- Author
-
Schini, Marian, Vilaca, Tatiane, Lui, Li-Yung, Ewing, Susan, Thompson, Austin, Vittinghoff, Eric, Bauer, Douglas, Bouxsein, Mary, Black, Dennis, and Eastell, Richard
- Subjects
BMD ,SABRE ,T-score ,osteoporosis ,treatment ,Humans ,Bone Density ,Female ,Male ,Aged ,Middle Aged ,Risk Factors ,Fractures ,Bone ,Bone Density Conservation Agents ,Randomized Controlled Trials as Topic ,Spinal Fractures ,Osteoporosis - Abstract
Some osteoporosis drug trials have suggested that treatment is more effective in those with low BMD measured by DXA. This study used data from a large set of randomized controlled trials (RCTs) to determine whether the anti-fracture efficacy of treatments differs according to baseline BMD. We used individual patient data from 25 RCTs (103 086 subjects) of osteoporosis medications collected as part of the FNIH-ASBMR SABRE project. Participants were stratified into FN BMD T-score subgroups (≤-2.5, > -2.5). We used Cox proportional hazard regression to estimate treatment effect for clinical fracture outcomes and logistic regression for the radiographic vertebral fracture outcome. We also performed analyses based on BMD quintiles. Overall, 42% had a FN BMD T-score ≤ -2.5. Treatment with anti-osteoporosis drugs led to significant reductions in fractures in both T-score ≤ -2.5 and > -2.5 subgroups. Compared to those with FN BMD T-score > -2.5, the risk reduction for each fracture outcome was greater in those with T-score ≤ -2.5, but only the all-fracture outcome reached statistical significance (interaction P = .001). Results were similar when limited to bisphosphonate trials. In the quintile analysis, there was significant anti-fracture efficacy across all quintiles for vertebral fractures and with greater effects on fracture risk reduction for non-vertebral, all, and all clinical fractures in the lower BMD quintiles (all interaction P ≤ .03). In summary, anti-osteoporotic medications reduced the risk of fractures regardless of baseline BMD. Significant fracture risk reduction with treatment for 4 of the 5 fracture endpoints was seen in participants with T-scores above -2.5, though effects tended to be larger and more significant in those with baseline T-scores
- Published
- 2024
5. Incidence of acute kidney injury and attributive mortality in acute respiratory distress syndrome randomized trials.
- Author
-
Antonucci, Edoardo, Garcia, Bruno, Chen, David, Matthay, Michael, Liu, Kathleen, and Legrand, Matthieu
- Subjects
Acute kidney injury ,Acute respiratory distress syndrome ,Attributable mortality ,Predictive enrichment ,Humans ,Acute Kidney Injury ,Respiratory Distress Syndrome ,Incidence ,Randomized Controlled Trials as Topic ,Male ,Female ,Middle Aged ,Aged - Abstract
PURPOSE: The development of acute kidney injury (AKI) after the acute respiratory distress syndrome (ARDS) reduces the chance of organ recovery and survival. The purpose of this study was to examine the AKI rate and attributable mortality in ARDS patients. METHODS: We performed an individual patient-data analysis including 10 multicenter randomized controlled trials conducted over 20 years. We employed a Super Learner ensemble technique, including a time-dependent analysis, to estimate the adjusted risk of AKI. We calculated the mortality attributable to AKI using an inverse probability of treatment weighting estimator integrated with the Super Learner. RESULTS: There were 5148 patients included in this study. The overall incidence of AKI was 43.7% (n = 2251). The adjusted risk of AKI ranged from 38.8% (95% confidence interval [CI], 35.7 to 41.9%) in ARMA, to 55.8% in ROSE (95% CI, 51.9 to 59.6%). 37.1% recovered rapidly from AKI, with a significantly lower recovery rate in recent trials (P
- Published
- 2024
6. Leveraging meta-regression to test if medication effects on cue-induced craving are associated with clinical efficacy.
- Author
-
Nieto, Steven, Du, Han, Meredith, Lindsay, Donato, Suzanna, Magill, Molly, and Ray, Lara
- Subjects
Alcohol cue-reactivity ,Alcohol use disorder ,Cue-induced craving ,Human laboratory ,Medication development ,Randomized clinical trials ,Humans ,Cues ,Craving ,Alcoholism ,Randomized Controlled Trials as Topic ,Treatment Outcome ,Alcohol Drinking - Abstract
RATIONALE: The alcohol cue exposure paradigm is a common method for evaluating new treatments for alcohol use disorder (AUD); however, it is unclear if medication-related reductions in cue-induced craving in the human laboratory can predict the clinical success of those medications in reducing alcohol consumption during clinical trials. OBJECTIVES: To use a novel meta-analytic approach to test whether medication effect sizes on cue-induced alcohol craving are associated with clinical efficacy in clinical trials. METHOD: We searched the literature for medications tested for AUD treatment using both the alcohol cue-reactivity paradigm and randomized clinical trials (RCTs). For alcohol cue-reactivity studies, we computed medication effect sizes for cue-induced alcohol craving (k = 36 studies, 15 medications). For RCTs, we calculated medication effect sizes for heavy drinking and abstinence (k = 139 studies, 19 medications). Using medication as the unit of analysis, we applied the Williamson-York bivariate weighted least squares estimation to account for errors in both independent and dependent variables. We also conducted leave-one-out cross validation simulations to examine the predictive utility of cue-craving medication effect sizes on RCT heavy drinking and abstinence endpoints. RESULTS: There was no significant relationship between medication effects on cue-induced alcohol craving in the human laboratory and medication effects on heavy drinking ( β ^ = 0.253, SE = 0.189, p = 0.090) and abstinence ( β ^ = 0.829, SE = 0.747, p = 0.133) in RCTs. CONCLUSIONS: The preliminary results of the current study challenge the assumption that alcohol cue-reactivity alone can be used as an early efficacy indicator for AUD pharmacotherapy development. These findings suggest that a wider range of early efficacy indicators and experimental paradigms be considered for Phase II testing of novel compounds.
- Published
- 2024
7. Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP): study protocol for a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose, adult survivors of after out-of-hospital cardiac arrest.
- Author
-
Meurer, William, Schmitzberger, Florian, Yeatts, Sharon, Ramakrishnan, Viswanathan, Abella, Benjamin, Aufderheide, Tom, Barsan, William, Benoit, Justin, Berry, Scott, Black, Joy, Bozeman, Nia, Broglio, Kristine, Brown, Jeremy, Brown, Kimberly, Carlozzi, Noelle, Caveney, Angela, Cho, Sung-Min, Chung-Esaki, Hangyul, Clevenger, Robert, Conwit, Robin, Cooper, Richelle, Crudo, Valentina, Daya, Mohamud, Harney, Deneil, Hsu, Cindy, Johnson, Nicholas, Khan, Imad, Khosla, Shaveta, Kline, Peyton, Kratz, Anna, Kudenchuk, Peter, Lewis, Roger, Madiyal, Chaitra, Meyer, Sara, Mosier, Jarrod, Mouammar, Marwan, Neth, Matthew, ONeil, Brian, Paxton, James, Perez, Sofia, Perman, Sarah, Sozener, Cemal, Speers, Mickie, Spiteri, Aimee, Stevenson, Valerie, Sunthankar, Kavita, Tonna, Joseph, Youngquist, Scott, Geocadin, Romergryko, and Silbergleit, Robert
- Subjects
Bayesian adaptive trial ,Cardiopulmonary Resuscitation ,Hypothermia ,Induced ,Neuroprotection ,Out-of-Hospital Cardiac Arrest ,Humans ,Hypothermia ,Induced ,Out-of-Hospital Cardiac Arrest ,Coma ,Time Factors ,Multicenter Studies as Topic ,Randomized Controlled Trials as Topic ,Treatment Outcome ,Recovery of Function ,Neuroprotection ,United States ,Comparative Effectiveness Research - Abstract
BACKGROUND: Cardiac arrest is a common and devastating emergency of both the heart and brain. More than 380,000 patients suffer out-of-hospital cardiac arrest annually in the USA. Induced cooling of comatose patients markedly improved neurological and functional outcomes in pivotal randomized clinical trials, but the optimal duration of therapeutic hypothermia has not yet been established. METHODS: This study is a multi-center randomized, response-adaptive, duration (dose) finding, comparative effectiveness clinical trial with blinded outcome assessment. We investigate two populations of adult comatose survivors of cardiac arrest to ascertain the shortest duration of cooling that provides the maximum treatment effect. The design is based on a statistical model of response as defined by the primary endpoint, a weighted 90-day mRS (modified Rankin Scale, a measure of neurologic disability), across the treatment arms. Subjects will initially be equally randomized between 12, 24, and 48 h of therapeutic cooling. After the first 200 subjects have been randomized, additional treatment arms between 12 and 48 h will be opened and patients will be allocated, within each initial cardiac rhythm type (shockable or non-shockable), by response adaptive randomization. As the trial continues, shorter and longer duration arms may be opened. A maximum sample size of 1800 subjects is proposed. Secondary objectives are to characterize: the overall safety and adverse events associated with duration of cooling, the effect on neuropsychological outcomes, and the effect on patient-reported quality of life measures. DISCUSSION: In vitro and in vivo studies have shown the neuroprotective effects of therapeutic hypothermia for cardiac arrest. We hypothesize that longer durations of cooling may improve either the proportion of patients that attain a good neurological recovery or may result in better recovery among the proportion already categorized as having a good outcome. If the treatment effect of cooling is increasing across duration, for at least some set of durations, then this provides evidence of the efficacy of cooling itself versus normothermia, even in the absence of a normothermia control arm, confirming previous RCTs for OHCA survivors of shockable rhythms and provides the first prospective controlled evidence of efficacy in those without initial shockable rhythms. TRIAL REGISTRATION: ClinicalTrials.gov NCT04217551. Registered on 30 December 2019.
- Published
- 2024
8. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
- Author
-
Goodman, Shaun G, Steg, Philippe Gabriel, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Harrington, Robert A, Jukema, J Wouter, White, Harvey D, Zeiher, Andreas M, Manvelian, Garen, Pordy, Robert, Poulouin, Yann, Stipek, Wanda, Garon, Genevieve, Schwartz, Gregory G, Steg, Ph Gabriel, Tricoci, Pierluigi, Roe, Matthew T, Mahaffey, Kenneth W, Edelberg, Jay M, Hanotin, Corinne, Lecorps, Guillaume, Moryusef, Angèle, Sasiela, William J, Tamby, Jean-François, Aylward, Philip E, Drexel, Heinz, Sinnaeve, Peter, Dilic, Mirza, Lopes, Renato D, Gotcheva, Nina N, Prieto, Juan-Carlos, Yong, Huo, López-Jaramillo, Patricio, Pećin, Ivan, Reiner, Zeljko, Ostadal, Petr, Poulsen, Steen Hvitfeldt, Viigimaa, Margus, Nieminen, Markku S, Danchin, Nicolas, Chumburidze, Vakhtang, Marx, Nikolaus, Liberopoulos, Evangelos, Valdovinos, Pablo Carlos Montenegro, Tse, Hung-Fat, Kiss, Robert Gabor, Xavier, Denis, Zahger, Doron, Valgimigli, Marco, Kimura, Takeshi, Kim, Hyo Soo, Kim, Sang-Hyun, Erglis, Andrejs, Laucevicius, Aleksandras, Kedev, Sasko, Yusoff, Khalid, López, Gabriel Arturo Ramos, Alings, Marco, Halvorsen, Sigrun, Flores, Roger M Correa, Sy, Rody G, Budaj, Andrzej, Morais, Joao, Dorobantu, Maria, Karpov, Yuri, Ristic, Arsen D, Chua, Terrance, Murin, Jan, Fras, Zlatko, Dalby, Anthony J, Tuñón, José, de Silva, H Asita, Hagström, Emil, Landmesser, Ulf, Chiang, Chern-En, Sritara, Piyamitr, Guneri, Sema, Parkhomenko, Alexander, Ray, Kausik K, Moriarty, Patrick M, Chaitman, Bernard, Kelsey, Sheryl F, Olsson, Anders G, and Rouleau, Jean-Lucien
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Patient Safety ,Clinical Research ,6.1 Pharmaceuticals ,Good Health and Well Being ,Humans ,Antibodies ,Monoclonal ,Humanized ,Anticholesteremic Agents ,Biomarkers ,Cardiovascular Diseases ,Cholesterol ,LDL ,Dyslipidemias ,PCSK9 Inhibitors ,Proprotein Convertase 9 ,Randomized Controlled Trials as Topic ,Serine Proteinase Inhibitors ,Time Factors ,Treatment Outcome ,ODYSSEY OUTCOMES Investigators ,Alirocumab ,Cholesterol ,PCSK9 ,Safety ,Cardiorespiratory Medicine and Haematology ,Pharmacology and Pharmaceutical Sciences ,Cardiovascular medicine and haematology ,Pharmacology and pharmaceutical sciences - Abstract
The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurrent ischaemic cardiovascular events with the monoclonal antibody to proprotein convertase subtilisin/kexin type 9 alirocumab, as well as lower all-cause death. These benefits were observed in the context of substantial and persistent lowering of low-density lipoprotein cholesterol with alirocumab compared with that achieved with placebo. The safety profile of alirocumab was indistinguishable from matching placebo except for a ∼1.7% absolute increase in local injection site reactions. Further, the safety of alirocumab compared with placebo was evident in vulnerable groups identified before randomization, such as the elderly and those with diabetes mellitus, previous ischaemic stroke, or chronic kidney disease. The frequency of adverse events and laboratory-based abnormalities was generally similar to that in placebo-treated patients. Thus, alirocumab appears to be a safe and effective lipid-modifying treatment over a duration of at least 5 years.
- Published
- 2024
9. Comparison of brace to observation in stable, radiological developmental dysplasia of the hip: a protocol for a global multicentre non-inferiority randomised trial.
- Author
-
Zomar, Bryn, Bone, Jeffrey, Nguyen, Vuong, Mulpuri, Kishore, Kelley, Simon, and Schaeffer, Emily
- Subjects
hip ,paediatric orthopaedics ,radiology & imaging ,randomized controlled trial ,ultrasound ,Humans ,Braces ,Infant ,Developmental Dysplasia of the Hip ,Multicenter Studies as Topic ,Watchful Waiting ,Equivalence Trials as Topic ,Female ,Radiography ,Infant ,Newborn ,Randomized Controlled Trials as Topic ,Ultrasonography ,Hip Dislocation ,Congenital ,Male - Abstract
INTRODUCTION: Brace treatment is common to address radiological dysplasia in infants with developmental dysplasia of the hip (DDH); however, it is unclear whether bracing provides significant benefit above careful observation by ultrasound. If observation alone is non-inferior to bracing for radiological dysplasia, unnecessary treatment may be avoided. Therefore, the purpose of this study is to determine whether observation is non-inferior to bracing for infants with radiological dysplasia. METHODS AND ANALYSIS: This will be a multicentre, global, randomised, non-inferiority trial performed under the auspices of a global prospective registry for infants and children diagnosed with DDH. Patients will be included if they present with radiological dysplasia (centred hip, alpha angle 43-60°, percent femoral head coverage greater than 35% measured on ultrasound) of a clinically stable hip under 3 months old. Patients will be excluded if they present with clinical hip instability, have received prior treatment or have known/suspected neuromuscular, collagen, chromosomal or lower-extremity congenital abnormalities or syndromic-associated hip abnormalities. Patients will be enrolled and randomised to undergo observation alone or brace treatment with a Pavlik harness for a minimum of 6 weeks. Follow-up visits will occur at 6 weeks, 1 year and 2 years post-enrolment. The primary outcome will be the norm-referenced acetabular index measured on the 2-year radiograph with a 3° non-inferiority margin. A total of 514 patients will be included.The study is anticipated to start in April 2024 and end in September 2028.The primary outcome will be compared between arms with a mixed-effects model with a random intercept for study centre, and a single covariate for the treatment group. If the lower bound of the 95% CI lies within 3° of the mean, we will treat this as evidence for non-inferiority. ETHICS AND DISSEMINATION: Ethics approval has been obtained from the lead sites ethics board (University of British Columbia, Childrens and Womens Research Ethics Board). Ethics approval will be obtained from the local ethics committees or institutional review boards at each institution prior to patient enrolment. It is intended that the results of this study shall be published in peer-reviewed journals and presented at suitable conferences. TRIAL REGISTRATION NUMBER: NCT05869851.
- Published
- 2024
10. Blurring cluster randomized trials and observational studies: Two-Stage TMLE for subsampling, missingness, and few independent units
- Author
-
Nugent, Joshua R, Marquez, Carina, Charlebois, Edwin D, Abbott, Rachel, and Balzer, Laura B
- Subjects
Mathematical Sciences ,Statistics ,Emerging Infectious Diseases ,Clinical Research ,Rare Diseases ,Infectious Diseases ,Tuberculosis ,Lung ,Infection ,Good Health and Well Being ,Humans ,Randomized Controlled Trials as Topic ,Observational Studies as Topic ,Cluster Analysis ,Data Interpretation ,Statistical ,Models ,Statistical ,Research Design ,Cluster randomized trials ,Double robustness ,Efficiency ,Group randomized trials ,Hierarchical data ,Missing data ,Multi-level data ,Super Learner ,Two-Stage targeted minimum loss-based estimation ,Genetics ,Statistics & Probability - Abstract
Cluster randomized trials (CRTs) often enroll large numbers of participants; yet due to resource constraints, only a subset of participants may be selected for outcome assessment, and those sampled may not be representative of all cluster members. Missing data also present a challenge: if sampled individuals with measured outcomes are dissimilar from those with missing outcomes, unadjusted estimates of arm-specific endpoints and the intervention effect may be biased. Further, CRTs often enroll and randomize few clusters, limiting statistical power and raising concerns about finite sample performance. Motivated by SEARCH-TB, a CRT aimed at reducing incident tuberculosis infection, we demonstrate interlocking methods to handle these challenges. First, we extend Two-Stage targeted minimum loss-based estimation to account for three sources of missingness: (i) subsampling; (ii) measurement of baseline status among those sampled; and (iii) measurement of final status among those in the incidence cohort (persons known to be at risk at baseline). Second, we critically evaluate the assumptions under which subunits of the cluster can be considered the conditionally independent unit, improving precision and statistical power but also causing the CRT to behave like an observational study. Our application to SEARCH-TB highlights the real-world impact of different assumptions on measurement and dependence; estimates relying on unrealistic assumptions suggested the intervention increased the incidence of TB infection by 18% (risk ratio [RR]=1.18, 95% confidence interval [CI]: 0.85-1.63), while estimates accounting for the sampling scheme, missingness, and within community dependence found the intervention decreased the incident TB by 27% (RR=0.73, 95% CI: 0.57-0.92).
- Published
- 2024
11. Types of Evidence Needed to Assess the Clinical Value of Diagnostic Imaging.
- Author
-
Stewart, Carly, Davenport, Matthew S, Miglioretti, Diana L, and Smith-Bindman, Rebecca
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Clinical Research ,Biomedical Imaging ,Patient Safety ,Clinical Trials and Supportive Activities ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Generic health relevance ,Humans ,Diagnostic Imaging ,Evidence-Based Medicine ,Randomized Controlled Trials as Topic - Abstract
AbstractThe evidence underlying the use of advanced diagnostic imaging is based mainly on diagnostic accuracy studies and not on well-designed trials demonstrating improved patient outcomes. This has led to an expansion of low-value and potentially harmful patient care and raises ethical issues around the widespread implementation of tests with incompletely known benefits and harms. Randomized clinical trials are needed to support the safety and effectiveness of imaging tests and should be required for clearance of most new technologies. Large, diverse cohort studies are needed to quantify disease risk associated with many imaging findings, especially incidental findings, to enable evidence-based management. The responsibility to minimize the use of tests with unknown or low value requires engagement of clinicians, medical societies, and the public.
- Published
- 2024
12. Enhancing patient-clinician collaboration during treatment decision-making: study protocol for a community-engaged, mixed method hybrid type 1 trial of collaborative decision skills training (CDST) for veterans with psychosis.
- Author
-
Treichler, Emily, McBride, Lauren, Gomez, Elissa, Jain, Joanna, Seaton, Sydney, Yu, Kasey, Oakes, David, Perivoliotis, Dimitri, Girard, Vanessa, Reznik, Samantha, Salyers, Michelle, Thomas, Michael, Spaulding, William, Granholm, Eric, Rabin, Borsika, and Light, Gregory
- Subjects
Implementation science ,Person-centered care ,Recovery ,Schizophrenia ,Shared decision-making ,Humans ,Psychotic Disorders ,Veterans ,Patient Participation ,Randomized Controlled Trials as Topic ,Cooperative Behavior ,Clinical Decision-Making ,Physician-Patient Relations ,Decision Making ,Shared ,United States ,Feasibility Studies ,California ,Decision Making ,United States Department of Veterans Affairs - Abstract
BACKGROUND: Patient participation in treatment decision making is a pillar of recovery-oriented care and is associated with improvements in empowerment and well-being. Although demand for increased involvement in treatment decision-making is high among veterans with serious mental illness, rates of involvement are low. Collaborative decision skills training (CDST) is a recovery-oriented, skills-based intervention designed to support meaningful patient participation in treatment decision making. An open trial among veterans with psychosis supported CDSTs feasibility and demonstrated preliminary indications of effectiveness. A randomized control trial (RCT) is needed to test CDSTs effectiveness in comparison with an active control and further evaluate implementation feasibility. METHODS: The planned RCT is a hybrid type 1 trial, which will use mixed methods to systematically evaluate the effectiveness and implementation feasibility of CDST among veterans participating in a VA Psychosocial Rehabilitation and Recovery Center (PRRC) in Southern California. The first aim is to assess the effectiveness of CDST in comparison with the active control via the primary outcome, collaborative decision-making behavior during usual care appointments between veterans and their VA mental health clinicians, and secondary outcomes (i.e., treatment engagement, satisfaction, and outcome). The second aim is to characterize the implementation feasibility of CDST within the VA PRRC using the Practical Robust Implementation and Sustainability Model framework, including barriers and facilitators within the PRRC context to support future implementation. DISCUSSION: If CDST is found to be effective and feasible, implementation determinants gathered throughout the study can be used to ensure sustained and successful implementation at this PRRC and other PRRCs and similar settings nationally. TRIAL REGISTRATION: ClinicalTrials.gov NCT04324944. Registered on March 27, 2020. Trial registration data can be found in Appendix 1.
- Published
- 2024
13. Supporting young women’s health through girl-friendly drug vendors in Lake Zone, Tanzania: protocol for the AmbassADDOrs for Health cluster-randomised controlled trial
- Author
-
Mnyippembe, Agatha, Sheira, Lila A, McCoy, Sandra I, Njau, Prosper F, Packel, Laura J, Hassan, Kassim, Solorzano-Barrera, Camila, Maokola, Werner, Dufour, Mi-Suk Kang, Sabasaba, Amon, and Liu, Jenny
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Sexually Transmitted Infections ,Teenage Pregnancy ,Clinical Research ,Behavioral and Social Science ,Clinical Trials and Supportive Activities ,Pediatric ,Women's Health ,Prevention ,Adolescent Sexual Activity ,HIV/AIDS ,Pediatric AIDS ,Contraception/Reproduction ,Infectious Diseases ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Reproductive health and childbirth ,Infection ,Good Health and Well Being ,Humans ,Tanzania ,Female ,Adolescent ,Young Adult ,HIV Infections ,Pregnancy ,Randomized Controlled Trials as Topic ,Commerce ,Clinical Trial ,Epidemiology ,HIV & AIDS ,Public health ,Clinical Sciences ,Public Health and Health Services ,Other Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
IntroductionAdverse sexual and reproductive health (SRH) outcomes, such as unplanned pregnancies and HIV infection, disproportionately affect adolescent girls and young women (AGYW; aged 15-24 years) in east Africa. Increasing uptake of preventive SRH services via innovative, youth-centred interventions is imperative to addressing disparities in SRH outcomes.Methods and analysisFrom 2018 to 2019, we used human-centred design to co-develop a theoretically driven HIV and pregnancy prevention intervention for AGYW at private drug shops called Accredited Drug Dispensing Outlets (ADDOs) in Tanzania. The result, Malkia Klabu (Queen Club), was a customer loyalty programme designed to strengthen ADDOs' role as SRH providers while encouraging uptake of critical SRH prevention products among AGYW. Malkia Klabu members had access to free contraceptives and oral HIV self-test (HIVST) kits and earned punches on a loyalty card for other shop purchases; punches were redeemable for small prizes. Our pilot among 40 shops showed that intervention ADDOs had higher AGYW patronage and distributed more HIVST kits and contraceptives to AGYW relative to business-as-usual (ie, client purchasing) comparison shops. We will conduct a cluster-randomised controlled trial (c-RCT) among 120-140 ADDOs in 40 health catchment areas in Shinyanga and Mwanza Regions (Lake Zone), Tanzania. ADDO shop recruitment includes a 1-month run-in with a tablet-based electronic inventory management system for tracking shop transactions, followed by enrolment, randomisation and a 24-month trial period. Our c-RCT evaluating the human-centred design-derived intervention will assess population impact on the primary outcomes of HIV diagnoses and antenatal care registrations, measured with routine health facility data. We will also assess secondary outcomes focusing on mechanisms of action, evaluate programme exposure and AGYW behaviour change in interviews with AGYW, and assess shop-level implementation strategies and fidelity.Ethics and disseminationEthical approval was granted from both the University of California, San Francisco and the Tanzanian National Institute for Medical Research. Study progress and final outcomes will be posted annually to the National Clinical Trials website; study dissemination will occur at conferences, peer-reviewed manuscripts and local convenings of stakeholders.Trial registration numberNCT05357144.
- Published
- 2024
14. Reducing intersectional stigma among transgender women in Brazil to promote uptake of HIV testing and PrEP: study protocol for a randomised controlled trial of Manas por Manas
- Author
-
Sevelius, Jae, Veras, Maria Amelia Sousa Mascena, Gomez, Jose Luis, Saggese, Gustavo, Mocello, Adrienne Rain, Bassichetto, Katia Cristina, Neilands, Torsten B, and Lippman, Sheri A
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Clinical Sciences ,Mental Health ,Social Determinants of Health ,Sexual and Gender Minorities (SGM/LGBT*) ,Health Disparities ,Behavioral and Social Science ,Women's Health ,Sexually Transmitted Infections ,Clinical Research ,Prevention ,Infectious Diseases ,Clinical Trials and Supportive Activities ,HIV/AIDS ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Infection ,Good Health and Well Being ,Humans ,Transgender Persons ,Brazil ,Female ,HIV Infections ,Pre-Exposure Prophylaxis ,Social Stigma ,Male ,Adult ,HIV Testing ,Randomized Controlled Trials as Topic ,Young Adult ,Adolescent ,Patient Acceptance of Health Care ,transgender persons ,HIV & AIDS ,primary prevention ,clinical trial ,health equity ,Public Health and Health Services ,Other Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
IntroductionGlobally, transgender ('trans') women experience extreme social and economic marginalisation due to intersectional stigma, defined as the confluence of stigma that results from the intersection of social identities and positions among those who are oppressed multiple times. Among trans women, gender-based stigma intersects with social positions such as engagement in sex work and substance use, as well as race-based stigma to generate a social context of vulnerability and increased risk of HIV acquisition. In Brazil, trans women are the 'most at-risk' group for HIV, with 55 times higher estimated odds of HIV infection than the general population; further, uptake of HIV testing and pre-exposure prophylaxis (PrEP) among trans women is significantly lower than other at-risk groups. Through extensive formative work, we developed Manas por Manas, a multilevel intervention using HIV prevention strategies with demonstrated feasibility and acceptability by trans women in Brazil, to address intersectional stigma and increase engagement in the HIV prevention continuum.Methods and analysisWe are conducting a two-arm randomised wait-list controlled trial of the intervention's efficacy in São Paulo, Brazil, to improve uptake of HIV testing and PrEP among transgender women (N=400). The primary outcomes are changes in HIV testing (self-testing and clinic based), changes in PrEP uptake and changes in PrEP persistence at baseline and follow-up assessment for 12 months at 3-month intervals.Ethics and disseminationThis study was approved by University of California, San Francisco Institutional Review Board (15-17910) and Comissão Nacional de Ética em Pesquisa (Research Ethics National Commission, CAAE: 25215219.8.0000.5479) in Brazil. Participants provided informed consent before enrolment. We are committed to collaboration with National Institutes of Health officials, other researchers, and health and social services communities for rapid dissemination of data and sharing of materials. The results will be published in peer-reviewed academic journals and scientific presentations.Trial registration numberNCT03081559.
- Published
- 2024
15. Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project.
- Author
-
Schini, Marian, Vilaca, Tatiane, Vittinghoff, Eric, Lui, Li-Yung, Ewing, Susan, Thompson, Austin, Bauer, Douglas, Bouxsein, Mary, Black, Dennis, and Eastell, Richard
- Subjects
BMD ,SABRE ,age ,bisphosphonates ,osteoporosis ,treatment ,Humans ,Female ,Aged ,Male ,Bone Density ,Middle Aged ,Randomized Controlled Trials as Topic ,Age Factors ,Fractures ,Bone ,Treatment Outcome ,Osteoporosis ,Aged ,80 and over ,Bone Density Conservation Agents - Abstract
There is a common belief that antiosteoporosis medications are less effective in older adults. This study used data from randomized controlled trials (RCTs) to determine whether the anti-fracture efficacy of treatments and their effects on BMD differ in people ≥70 compared to those
- Published
- 2024
16. Reanalysis of cluster randomised trial data to account for exposure misclassification using a per-protocol and complier-restricted approach.
- Author
-
Tanamas, Stephanie, Indriani, Citra, Ahmad, Riris, Utarini, Adi, Jewell, Nicholas, Simmons, Cameron, Anders, Katherine, and Dufault, Suzanne
- Subjects
Humans ,Wolbachia ,Aedes ,Animals ,Dengue ,Mosquito Vectors ,Randomized Controlled Trials as Topic ,Cluster Analysis ,Mosquito Control ,Female - Abstract
The intention-to-treat (ITT) analysis of the Applying Wolbachia to Eliminate Dengue (AWED) trial estimated a protective efficacy of 77.1% for participants resident in areas randomised to receive releases of wMel-infected Aedes aegypti mosquitoes, an emerging dengue preventive intervention. The limiting assumptions of ITT analyses in cluster randomised trials and the mobility of mosquitoes and humans across cluster boundaries indicate the primary analysis is likely to underestimate the full public health benefit. Using spatiotemporally-resolved data on the distribution of Wolbachia mosquitoes and on the mobility of AWED participants (n = 6306), we perform complier-restricted and per-protocol re-examinations of the efficacy of the Wolbachia intervention. Increased intervention efficacy was estimated in all analyses by the refined exposure measures. The complier-restricted analysis returned an estimated efficacy of 80.7% (95% CI 65.9, 89.0) and the per-protocol analysis estimated 82.7% (71.7, 88.4) efficacy when comparing participants with an estimated wMel exposure of ≥ 80% compared to those with
- Published
- 2024
17. Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials.
- Author
-
Johansson, Harriet, Bellerba, Federica, Macis, Debora, Bertelsen, Bjørn-Erik, Guerrieri-Gonzaga, Aliana, Aristarco, Valentina, Viste, Kristin, Mellgren, Gunnar, Di Cola, Giulia, Costantino, Jemos, Scalbert, Augustin, Sears, Dorothy, Gandini, Sara, DeCensi, Andrea, and Bonanni, Bernardo
- Subjects
Cytokines ,Inflammation ,Recurrence biomarkers ,Sex hormones ,Weight loss ,Humans ,Metformin ,Female ,Breast Neoplasms ,Cancer Survivors ,Adipokines ,Middle Aged ,Life Style ,Aged ,Obesity ,Insulin Resistance ,Hypoglycemic Agents ,Randomized Controlled Trials as Topic - Abstract
PURPOSE: We investigated the effect of metformin and lifestyle intervention on metabolic, inflammatory, and steroid biomarkers of breast cancer (BC) recurrence risk in two intervention trials among BC survivors with overweight or obesity. METHODS: Baseline and follow-up serum samples collected during the two trials were analyzed and data pooled. The USA trial (Reach for Health) included postmenopausal BC survivors (n = 333) randomly assigned to 6-month metformin vs placebo and lifestyle intervention (LSI) vs control (2 × 2 factorial design). The Italian trial (MetBreCS) included BC survivors (n = 40) randomized to 12-month metformin vs placebo. Insulin resistance (HOMA-IR), adipokines, cytokines, and steroids were measured. RESULTS: Metformin compared to placebo showed a favorable decrease in leptin (- 8.8 vs - 3.5 ng/mL; p
- Published
- 2024
18. Comparison of safety and effectiveness of antiretroviral therapy regimens among pregnant women living with HIV at preconception or during pregnancy: a systematic review and network meta-analysis of randomized trials.
- Author
-
Mehrabi, Fatemeh, Karamouzian, Mohammad, Farhoudi, Behnam, Moradi Falah Langeroodi, Shahryar, Mehmandoost, Soheil, Abbaszadeh, Samaneh, Motaghi, Shahrzad, Mirzazadeh, Ali, Sadeghirad, Behnam, and Sharifi, Hamid
- Subjects
Antiretroviral agents ,HIV infection ,Infant ,Pregnant women ,Vertical transmission ,Female ,Pregnancy ,Infant ,Newborn ,Humans ,Pregnancy Complications ,Infectious ,Pregnant Women ,Stillbirth ,Network Meta-Analysis ,Premature Birth ,Infectious Disease Transmission ,Vertical ,Randomized Controlled Trials as Topic ,HIV Infections - Abstract
BACKGROUND: Mother-to-child transmission is the primary cause of HIV cases among children. Antiretroviral therapy (ART) plays a critical role in preventing mother-to-child transmission and reducing HIV progression, morbidity, and mortality among mothers. However, after more than two decades of ART during pregnancy, the comparative effectiveness and safety of ART medications during pregnancy are unclear, and existing evidence is contradictory. This study aimed to assess the effectiveness and safety of different ART regimens among pregnant women living with HIV at preconception or during pregnancy. METHODS: We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science. We included randomized trials that enrolled pregnant women living with HIV and randomized them to receive ART for at least four weeks. Pairs of reviewers independently completed screening for eligible studies, extracted data, and assessed the risk of bias using the Cochrane risk of bias tool. Our outcomes of interest included low birth weight, stillbirth, preterm birth, mother-to-child transmission of HIV, neonatal death, and congenital anomalies. Network meta-analysis was performed using a random-effects frequentist model, and the certainty of evidence was evaluated using the GRADE approach. RESULTS: We found 14 eligible randomized trials enrolling 9,561 pregnant women. The median duration of ART uptake ranged from 6.0 to 17.4 weeks. No treatment was statistically better than a placebo in reducing the rate of neonatal mortality, stillbirth, congenital defects, preterm birth, or low birth weight deliveries. Compared to placebo, zidovudine (ZDV)/lamivudine (3TC) and ZDV monotherapy likely reduce mother-to-child transmission (odds ratio (OR): 0.13; 95% CI: 0.05 to 0.31, high-certainty; and OR: 0.50; 95% CI: 0.33 to 0.74, moderate-certainty). Moderate-certainty evidence suggested that ZDV/3TC was associated with decreased odds of stillbirth (OR: 0.47; 95% CI: 0.09 to 2.60). CONCLUSIONS: Our analysis provides high- to moderate-certainty evidence that ZDV/3TC and ZDV are more effective in reducing the odds of mother-to-child transmission, with ZDV/3TC also demonstrating decreased odds of stillbirth. Notably, our findings suggest an elevated odds of stillbirth and preterm birth associated with all other ART regimens.
- Published
- 2024
19. Fragility of overactive bladder medication clinical trials: A systematic review
- Author
-
Li, Kevin D, Venishetty, Nikit, Fernandez, Adrian M, Hakam, Nizar, Ghaffar, Umar, Gupta, Shiv, Patel, Hiren V, and Breyer, Benjamin N
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Urologic Diseases ,Clinical Research ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,anticholinergics ,B3 agonizts ,clinical trials ,fragility ,fragility index ,fragility quotient ,mirabegron ,overactive bladder ,oxybutynin ,systematic review ,Humans ,Cholinergic Antagonists ,Treatment Outcome ,Urinary Bladder ,Overactive ,Randomized Controlled Trials as Topic ,Neurosciences ,Urology & Nephrology ,Clinical sciences - Abstract
PurposeOveractive bladder (OAB) syndrome significantly impairs quality of life, often necessitating pharmacological interventions with associated risks. The fragility of OAB trial outcomes, as measured by the fragility index (FI: smallest number of event changes to reverse statistical significance) and quotient (FQ: FI divided by total sample size expressed as a percentage), is critical yet unstudied.Materials and methodsWe conducted a systematic search for randomized controlled trials on OAB medications published between January 2000 and August 2023. Inclusion criteria were trials with two parallel arms reporting binary outcomes related to OAB medications. We extracted trial details, outcomes, and statistical tests employed. We calculated FI and FQ, analyzing associations with trial characteristics through linear regression.ResultsWe included 57 trials with a median sample size of 211 participants and a 12% median lost to follow-up. Most studies investigated anticholinergics (37/57, 65%). The median FI/FQ was 5/3.5%. Larger trials were less fragile (median FI 8; FQ 1.0%) compared to medium (FI: 4; FQ 2.5%) and small trials (FI: 4; FQ 8.3%). Double-blinded studies exhibited higher FQs (median 2.9%) than unblinded trials (6.7%). Primary and secondary outcomes had higher FIs (median 5 and 6, respectively) than adverse events (FI: 4). Each increase in 10 participants was associated with a +0.19 increase in FI (p
- Published
- 2024
20. Life skills and reproductive health empowerment intervention for newly married women and their families to reduce unintended pregnancy in India: protocol for the TARANG cluster randomised controlled trial
- Author
-
Diamond-Smith, Nadia, Gopalakrishnan, Lakshmi, Leslie, Hannah, Katz, Elizabeth, Harper, Cynthia, Weiser, Sheri, and Patil, Sumeet R
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Prevention ,Clinical Trials and Supportive Activities ,Pediatric ,Adolescent Sexual Activity ,Contraception/Reproduction ,Women's Health ,Behavioral and Social Science ,Clinical Research ,Teenage Pregnancy ,Social Determinants of Health ,Prevention of disease and conditions ,and promotion of well-being ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Reproductive health and childbirth ,Good Health and Well Being ,Gender Equality ,Humans ,Female ,India ,Pregnancy ,Empowerment ,Adult ,Young Adult ,Adolescent ,Reproductive Health ,Pregnancy ,Unplanned ,Family Planning Services ,Randomized Controlled Trials as Topic ,Marriage ,Contraception ,Rural Population ,Contraception Behavior ,Male ,Health ,PUBLIC HEALTH ,Pregnant Women ,Clinical Sciences ,Public Health and Health Services ,Other Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
IntroductionIn South Asia, younger women have high rates of unmet need for family planning and low empowerment. Life skills interventions can equip young women with agency, but the effectiveness of these interventions in reproductive and sexual autonomy and contraception has not been examined.Methods and analysisA two-arm, parallel, cluster randomised controlled trial will evaluate the impact of TARANG (Transforming Actions for Reaching and Nurturing Gender Equity and Empowerment), a life skills and reproductive health empowerment group-based intervention for newly married women, compared with usual services in the community in rural and tribal Rajasthan, India. TARANG will also provide light-touch sessions to husbands and mothers-in-law of newly married women. We will test the impact of TARANG in 80 village clusters among 800 eligible households comprising newly married women aged 18-25 years who are at risk of pregnancy but do not want a pregnancy within 1 year at the time of enrolment, their husbands and mothers-in-law who consent to participate. Women in the intervention villages will receive 14 sessions over a 6-month period, while husbands and mothers-in-law will receive 1 and 4 sessions (respectively) each. Three rounds of surveys will be collected over 18 months. Control villages will receive the intervention after the endline surveys. Primary outcomes include rate of unintended pregnancy and modern contraceptive use. We plan to start recruitment of participants and data collection in April 2024. We will estimate unadjusted and adjusted intention-to-treat effects using survival analysis and mixed models.Ethics and disseminationStudy protocols have been reviewed and approved by the human subjects review boards at the University of California, San Francisco, and the Centre for Media Studies, India (IRB00006230) and ACE Independent Ethics Committee, Bangalore (NET0062022). Results will be disseminated in international peer-reviewed journals and conferences, to stakeholders including local government and non-governmental organisations, and directly to the communities and individuals that participated in the intervention.Trial registration numberNCT06024616.
- Published
- 2024
21. Child Health and Infection with Low Density (CHILD) malaria: a protocol for a randomised controlled trial to assess the long-term health and socioeconomic impacts of testing and treating low-density malaria infection among children in Tanzania.
- Author
-
Gutapaka, Nicolaus, Sumari, Deborah, Loss, Georg, Athuman, Thabit, Nyandele, Jane, Cummins, Hannah, Chemba, Mwajuma, Benjamin-Chung, Jade, Gangar, Pamela, Wu, Xue, Smith, Jennifer, Chen, Ingrid, Dorsey, Grant, Fink, Günther, Olotu, Ally, Hsiang, Michelle, and Jebiwott, Sylvia
- Subjects
Clinical Trial ,Epidemiology ,IMMUNOLOGY ,Malaria ,Molecular diagnostics ,Randomized Controlled Trial ,Child ,Humans ,Antimalarials ,Artemether ,Artemether ,Lumefantrine Drug Combination ,Child Health ,Malaria ,Randomized Controlled Trials as Topic ,Socioeconomic Factors ,Tanzania ,Infant ,Child ,Preschool - Abstract
INTRODUCTION: As malaria declines, low-density malaria infections (LMIs) represent an increasing proportion of infections and may have negative impacts on child health and cognition, necessitating development of targeted and effective solutions. This trial assesses the health, cognitive and socioeconomic impact of two strategies for detecting and treating LMI in a low transmission setting. METHODS AND ANALYSIS: The study is a 3-arm open-label individually randomised controlled trial enrolling 600 children aged 6 months to 10 years in Bagamoyo district, Tanzania. Children are randomised to one of three arms: active case detection with molecular (ACDm) testing by high volume quantitative PCR (qPCR), passive case detection also with molecular testing (PCDm) and a control of standard PCD using rapid diagnostics tests (RDTs). Over the 2-year trial, ACDm participants receive malaria testing using RDT and qPCR three times annually, and malaria testing by RDT only when presenting with fever. PCDm and PCD participants receive malaria testing by RDT and qPCR or RDT only, respectively, when presenting with fever. RDT or qPCR positive participants with uncomplicated malaria are treated with artemether lumefantrine. The primary outcome is cumulative incidence of all-cause sick visits. Secondary outcomes include fever episodes, clinical failure after fever episodes, adverse events, malaria, non-malarial infection, antibiotic use, anaemia, growth faltering, cognition and attention, school outcomes, immune responses, and socioeconomic effects. Outcomes are assessed through monthly clinical assessments and testing, and baseline and endline neurodevelopmental testing. The trial is expected to provide key evidence and inform policy on health, cognitive and socioeconomic impact of interventions targeting LMI in children. ETHICS AND DISSEMINATION: Study is approved by Tanzania NatHREC and institutional review boards at University of California San Francisco and Ifakara Health Institute. Findings will be reported on ClinicalTrials.gov, in peer-reviewed journals and through stakeholder meetings. TRIAL REGISTRATION NUMBER: NCT05567016.
- Published
- 2024
22. Heart rate and breathing effects on attention and memory (HeartBEAM): study protocol for a randomized controlled trial in older adults.
- Author
-
Nashiro, Kaoru, Yoo, Hyun, Cho, Christine, Kim, Andy, Nasseri, Padideh, Min, Jungwon, Dahl, Martin, Mercer, Noah, Choupan, Jeiran, Choi, Paul, Lee, Hye, Choi, David, Alemu, Kalekirstos, Herrera, Alexandra, Ng, Nicole, Thayer, Julian, and Mather, Mara
- Subjects
Alzheimer’s disease ,Amyloid beta ,Brain games ,Cognition ,Cognitive training ,Heart rate oscillations ,Heart rate variability biofeedback ,Memory ,Perivascular space ,Slow-paced breathing ,Humans ,Aged ,Heart Rate ,Respiration ,Cognition ,Biofeedback ,Psychology ,Attention ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND: In healthy people, the fight-or-flight sympathetic system is counterbalanced by the rest-and-digest parasympathetic system. As we grow older, the parasympathetic system declines as the sympathetic system becomes hyperactive. In our prior heart rate variability biofeedback and emotion regulation (HRV-ER) clinical trial, we found that increasing parasympathetic activity through daily practice of slow-paced breathing significantly decreased plasma amyloid-β (Aβ) in healthy younger and older adults. In healthy adults, higher plasma Aβ is associated with greater risk of Alzheimers disease (AD). Our primary goal of this trial is to reproduce and extend our initial findings regarding effects of slow-paced breathing on Aβ. Our secondary objectives are to examine the effects of daily slow-paced breathing on brain structure and the rate of learning. METHODS: Adults aged 50-70 have been randomized to practice one of two breathing protocols twice daily for 9 weeks: (1) slow-paced breathing condition involving daily cognitive training followed by slow-paced breathing designed to maximize heart rate oscillations or (2) random-paced breathing condition involving daily cognitive training followed by random-paced breathing to avoid increasing heart rate oscillations. The primary outcomes are plasma Aβ40 and Aβ42 levels and plasma Aβ42/40 ratio. The secondary outcomes are brain perivascular space volume, hippocampal volume, and learning rates measured by cognitive training performance. Other pre-registered outcomes include plasma pTau-181/tTau ratio and urine Aβ42. Recruitment began in January 2023. Interventions are ongoing and will be completed by the end of 2023. DISCUSSION: Our HRV-ER trial was groundbreaking in demonstrating that a behavioral intervention can reduce plasma Aβ levels relative to a randomized control group. We aim to reproduce these findings while testing effects on brain clearance pathways and cognition. TRIAL REGISTRATION: ClinicalTrials.gov NCT05602220. Registered on January 12, 2023.
- Published
- 2024
23. Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
- Author
-
Weir, Isabelle, Dufault, Suzanne, and Phillips, Patrick
- Subjects
Clinical trials ,Estimands ,Tuberculosis ,Humans ,Data Interpretation ,Statistical ,Randomized Controlled Trials as Topic ,Retrospective Studies ,Tuberculosis - Abstract
BACKGROUND: Randomized trials for the treatment of tuberculosis (TB) rely on a composite primary outcome to capture unfavorable treatment responses. However, variability between trials in the outcome definition and estimation methods complicates across-trial comparisons and hinders the advancement of treatment guidelines. The International Council for Harmonization (ICH) provides international regulatory standards for clinical trials. The estimand framework outlined in the recent ICH E9(R1) addendum offers a timely opportunity for randomized trials of TB treatment to adopt broadly standardized outcome definitions and analytic approaches. We previously proposed and defined four estimands for use in this context. Our objective was to evaluate how the use of these estimands and choice of estimation method impacts results and interpretation of a large phase III TB trial. METHODS: We reanalyzed participant-level data from the REMoxTB trial. We applied four estimands and various methods of estimation to assess non-inferiority of both novel 4-month treatment regimens against standard of care. RESULTS: With each of the four estimands, we reached the same conclusion as the original trial analysis that the novel regimens were not non-inferior to standard of care. Each estimand and method of estimation gave similar estimates of the treatment effect with fluctuations in variance and differences driven by the methods applied for handling intercurrent events. CONCLUSIONS: Our application of estimands defined by the ICH E9 (R1) addendum offers a formalized framework for addressing the primary TB treatment trial objective and can promote uniformity in future trials by limiting heterogeneity in trial outcome definitions. We demonstrated the utility of our proposal using data from the REMoxTB randomized trial. We outlined methods for estimating each estimand and found consistent conclusions across estimands. We recommend future late-phase TB treatment trials to implement some or all of our estimands to promote rigorous outcome definitions and reduce variability between trials. TRIAL REGISTRATION: ClinicalTrials.gov NCT00864383. Registered on March 2009.
- Published
- 2024
24. Comparative effectiveness of implementation strategies for Accelerating Cervical Cancer Elimination through the integration of Screen-and-treat Services (ACCESS study): protocol for a cluster randomized hybrid type III trial in Nigeria.
- Author
-
Olakunde, Babayemi, Itanyi, Ijeoma, Olawepo, John, Liu, Lin, Bembir, Chinenye, Idemili-Aronu, Ngozi, Lasebikan, Nwamaka, Onyeka, Tonia, Dim, Cyril, Chigbu, Chibuike, Ezeanolue, Echezona, and Aarons, Gregory
- Subjects
Africa ,Cervical cancer ,Implementation science ,Nigeria ,RE-AIM ,Women living with HIV ,EPIS framework ,Exploration ,Preparation ,Implementation ,and Sustainment framework ,Humans ,Female ,Nigeria ,Uterine Cervical Neoplasms ,Self Efficacy ,HIV Infections ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND: Despite the increased risk of cervical cancer (CC) among women living with HIV (WLHIV), CC screening and treatment (CCST) rates remain low in Africa. The integration of CCST services into established HIV programs in Africa can improve CC prevention and control. However, the paucity of evidence on effective implementation strategies (IS) has limited the success of integration in many countries. In this study, we seek to identify effective IS to enhance the integration of CCST services into existing HIV programs in Nigeria. METHODS: Our proposed study has formative and experimental activities across the four phases of the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework. Through an implementation mapping conducted with stakeholders in the exploration phase, we identified a core package of IS (Core) and an enhanced package of IS (Core+) mostly selected from the Expert Recommendations for Implementing Change. In the preparation phase, we refined and tailored the Core and Core+ IS with the implementation resource teams for local appropriateness. In the implementation phase, we will conduct a cluster-randomized hybrid type III trial to assess the comparative effectiveness of Core versus Core+. HIV comprehensive treatment sites (k = 12) will be matched by region and randomized to Core or Core+ in the ratio of 1:1 stratified by region. In the sustainment phase, we will assess the sustainment of CCST at each site. The study outcomes will be assessed using RE-AIM: reach (screening rate), adoption (uptake of IS by study sites), IS fidelity (degree to which the IS occurred according to protocol), clinical intervention fidelity (delivery of CC screening, onsite treatment, and referral according to protocol), clinical effectiveness (posttreatment screen negative), and sustainment (continued integrated CCST service delivery). Additionally, we will descriptively explore potential mechanisms, including organizational readiness, implementation climate, CCST self-efficacy, and implementation intentions. DISCUSSION: The assessment of IS to increase CCST rates is consistent with the global plan of eliminating CC as a public health threat by 2030. Our study will identify a set of evidence-based IS for low-income settings to integrate evidence-based CCST interventions into routine HIV care in order to improve the health and life expectancy of WLHIV. TRIAL REGISTRATION: Prospectively registered on November 7, 2023, at ClinicalTrials.gov no. NCT06128304. https://classic. CLINICALTRIALS: gov/ct2/show/study/NCT06128304.
- Published
- 2024
25. Behavioral economic and wellness-based approaches for reducing alcohol use and consequences among diverse non-student emerging adults: study protocol for Project BLUE, a randomized controlled trial.
- Author
-
Murphy, James, Dennhardt, Ashley, Tempchin, Jacob, Colgonis, Hannah, McDevitt-Murphy, Meghan, Berlin, Kristoffer, and Borsari, Brian
- Subjects
Alcohol misuse ,Behavioral economics ,Brief motivational intervention ,Emerging adulthood ,Substance-free activities ,Humans ,Female ,Male ,Economics ,Behavioral ,Alcohol Drinking ,Motivation ,Alcoholism ,Students ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND: Emerging adults (EAs) who are not 4-year college students nor graduates are at elevated risk for lifetime alcohol use disorder, comorbid drug use, and mental health symptoms, compared to college graduates. There is a need for tailored brief alcohol intervention (BAI) approaches to reduce alcohol risk and to facilitate healthy development in this high-risk population. Most BAIs include a single session focused on discussing risks associated with drinking and correcting normative beliefs about drinking rates. EAs may benefit from additional elements that enhance general wellness. The substance-free activity session (SFAS) aims to clarify life goals and values and increase goal-directed activities that provide alternatives to alcohol use, and the relaxation training (RT) session teaches relaxation and stress reduction skills. METHODS: The present study is a randomized 3-group (BAI + SFAS vs. RT + SFAS vs. education control) trial with 525 EAs (175 per group; estimated 50% women and 50% African American) who report recent risky drinking and who are not students or graduates of 4-year colleges. Participants will have the option of completing the intervention sessions in person or via a secure video teleconference. Levels of drinking and alcohol-related problems will be evaluated at baseline and 1, 3, 6, and 12 months post-intervention. The primary hypothesis is that both BAI + SFAS and RT + SFAS participants will report significantly greater reductions in alcohol use and problems relative to education control participants, with no differences in outcomes between the two active treatment conditions. DISCUSSION: The results of this study will inform alcohol prevention efforts for high-risk community dwelling emerging adults. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04776278.
- Published
- 2024
26. Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.
- Author
-
Benjamin, David, Haslam, Alyson, and Prasad, Vinay
- Subjects
cardiovascular drugs ,drug repurposing ,oncology trials ,randomized trials ,Humans ,Angiotensin-Converting Enzyme Inhibitors ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Carcinoma ,Non-Small-Cell Lung ,Angiotensin Receptor Antagonists ,Lung Neoplasms ,Randomized Controlled Trials as Topic ,Anti-Inflammatory Agents ,Non-Steroidal ,Anti-Inflammatory Agents ,Aspirin ,Antihypertensive Agents ,Metformin - Abstract
BACKGROUND: Due to encouraging pre-clinical data and supportive observational studies, there has been growing interest in applying cardiovascular drugs (including aspirin, angiotensin-converting enzyme [ACE] inhibitors, statins, and metformin) approved to treat diseases such as hypertension, hyperlipidemia, and diabetes mellitus to the field of oncology. Moreover, given growing costs with cancer care, these medications have offered a potentially more affordable avenue to treat or prevent recurrence of cancer. We sought to investigate the anti-cancer effects of drugs repurposed from cardiology or anti-inflammatories to treat cancer. We specifically evaluated the following drug classes: HMG-CoA reductase inhibitors (statins), cyclo-oxygenase inhibitors, aspirin, metformin, and both angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors. We also included non-steroidal anti-inflammatory drugs (NSAIDs) because they exert a similar mechanism to aspirin by blocking prostaglandins and reducing inflammation that is thought to promote the development of cancer. METHODS: We performed a systematic literature review using PubMed and Web of Science with search terms including aspirin, NSAID, statin (including specific statin drug names), metformin, ACE inhibitors, and ARBs (including specific anti-hypertensive drug names) in combination with cancer. Searches were limited to human studies published between 2000 and 2023. MAIN OUTCOMES AND MEASURES: The number and percentage of studies reported positive results and pooled estimates of overall survival, progression-free survival, response, and disease-free survival. RESULTS: We reviewed 3094 titles and included 67 randomized clinical trials. The most common drugs that were tested were metformin (n = 21; 30.9%), celecoxib (n = 20; 29.4%), and simvastatin (n = 8; 11.8%). There was only one study that tested cardiac glycosides and none that studied ACE inhibitors. The most common tumor types were non-small-cell lung cancer (n = 19; 27.9%); breast (n = 8; 20.6%), colorectal (n = 7; 10.3%), and hepatocellular (n = 6; 8.8%). Most studies were conducted in a phase II trial (n = 38; 55.9%). Most studies were tested in metastatic cancers (n = 49; 72.1%) and in the first-line setting (n = 36; 521.9%). Four studies (5.9%) were stopped early because of difficulty with accrual. The majority of studies did not demonstrate an improvement in either progression-free survival (86.1% of studies testing progression-free survival) or in overall survival (94.3% of studies testing overall survival). Progression-free survival was improved in five studies (7.4%), and overall survival was improved in three studies (4.4%). Overall survival was significantly worse in two studies (3.8% of studies testing overall survival), and progression-free survival was worse in one study (2.8% of studies testing progression-free survival). CONCLUSIONS AND RELEVANCE: Despite promising pre-clinical and population-based data, cardiovascular drugs and anti-inflammatory medications have overall not demonstrated benefit in the treatment or preventing recurrence of cancer. These findings may help guide future potential clinical trials involving these medications when applied in oncology.
- Published
- 2024
27. Acceptability of the Dapivirine Vaginal Ring and Oral Truvada Among African Users in Late-Stage of Pregnancy.
- Author
-
Hawley, Imogen, Fairlie, Lee, Bunge, Katie, Mathebula, Florence, Etima, Juliane, Mutero, Prisca, Senyama, Linly, Mayo, Ashley, Stoner, Marie, Piper, Jeanna, Balan, Ivan, van der Straten, Ariane, and Montgomery, Elizabeth
- Subjects
Dapivirine ring ,HIV prevention ,Malawi ,Oral PrEP ,Pregnant women ,South Africa ,Uganda ,Zimbabwe ,Female ,Humans ,Pregnancy ,Africa ,Anti-HIV Agents ,Contraceptive Devices ,Female ,Emtricitabine ,Tenofovir Disoproxil Fumarate Drug Combination ,HIV Infections ,Pyrimidines ,Randomized Controlled Trials as Topic ,Clinical Trials ,Phase III as Topic - Abstract
The Microbicide Trials Network 042 study (MTN-042/DELIVER) is a two-arm, randomized, open-label Phase 3b trial that is evaluating the safety, adherence, and acceptability of the monthly ring and daily oral PrEP among HIV-uninfected pregnant people in four African countries. This analysis focuses on acceptability data captured qualitatively from a subset (n = 48) of the 150 people in the first cohort of the trial who were enrolled in late-stage pregnancy at 36 to 38 weeks gestational age and followed until after delivery. Single IDIs were conducted by trained interviewers at each clinic site using a semi-structured guide. Data excerpts of key codes pertaining to acceptability, pregnancy, and maternal health were summarized, reviewed and interpreted by multinational analyst teams. Although the product use period was relatively short, the data suggested several acceptability findings that may directly translate to longer durations of product use in pregnancy. The first was the overarching maternal sentiment that being able to protect both oneself and their baby was highly valued. The second was the importance of counseling support from providers not only because participants used methods that might generate side effects, but because pregnancy itself is a period with its own set of side effects. The third was that, similar to non-pregnant participants in other trials, here study products were generally liked and described as easy to use. Concerns about ring and oral PrEP use could be addressed with provider counseling and support and should form an essential component rollout among pregnant people.
- Published
- 2024
28. Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis (BASIS): protocol of a prospective, multicentre, randomised, controlled trial.
- Author
-
Wang, Yongjun, Wang, Yilong, Miao, Zhongrong, Sun, Xuan, Yang, Ming, Sun, Dapeng, Peng, Guangge, Deng, Yiming, Zhao, Xingquan, Liu, Liping, Ma, Ning, Gao, Feng, Mo, Dapeng, and Yu, Wengui
- Subjects
Angiography ,Angioplasty ,Atherosclerosis ,Humans ,Adult ,Middle Aged ,Aged ,Aged ,80 and over ,Constriction ,Pathologic ,Stents ,Angioplasty ,Balloon ,Arteries ,Ischemic Stroke ,Randomized Controlled Trials as Topic ,Multicenter Studies as Topic - Abstract
BACKGROUND: The superiority of balloon angioplasty plus aggressive medical management (AMM) to AMM alone for symptomatic intracranial artery stenosis (sICAS) on efficacy and safety profiles still lacks evidence from randomised controlled trials (RCTs). AIM: To demonstrate the design of an RCT on balloon angioplasty plus AMM for sICAS. DESIGN: Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis (BASIS) trial is a multicentre, prospective, randomised, open-label, blinded end-point trial to investigate whether balloon angioplasty plus AMM could improve clinical outcome compared with AMM alone in patients with sICAS. Patients eligible in BASIS were 35-80 years old, with a recent transient ischaemic attack within the past 90 days or ischaemic stroke between 14 days and 90 days prior to enrolment due to severe atherosclerotic stenosis (70%-99%) of a major intracranial artery. The eligible patients were randomly assigned to receive balloon angioplasty plus AMM or AMM alone at a 1:1 ratio. Both groups will receive identical AMM, including standard dual antiplatelet therapy for 90 days followed by long-term single antiplatelet therapy, intensive risk factor management and life-style modification. All participants will be followed up for 3 years. STUDY OUTCOMES: Stroke or death in the next 30 days after enrolment or after balloon angioplasty procedure of the qualifying lesion during follow-up, or any ischaemic stroke or revascularisation from the qualifying artery after 30 days but before 12 months of enrolment, is the primary outcome. DISCUSSION: BASIS trail is the first RCT to compare the efficacy and safety of balloon angioplasty plus AMM to AMM alone in sICAS patients, which may provide an alternative perspective for treating sICAS. TRIAL REGISTRATION NUMBER: NCT03703635; https://www. CLINICALTRIALS: gov.
- Published
- 2024
29. Rudi Kundini, Pamoja Kundini (RKPK): study protocol for a hybrid type 1 randomized effectiveness-implementation trial using data science and economic incentive strategies to strengthen the continuity of care among people living with HIV in Tanzania.
- Author
-
Packel, Laura, Mlowe, Matilda, Ulenga, Nzovu, Mwenda, Natalino, Njau, Prosper, Dow, William, Wang, Jingshen, Sabasaba, Amon, McCoy, Sandra, and Kadota, Jillian
- Subjects
Conditional cash transfers ,Economic incentives ,Effectiveness-implementation hybrid ,HIV/AIDS ,Tanzania ,Humans ,Motivation ,Tanzania ,Data Science ,HIV Infections ,Continuity of Patient Care ,Randomized Controlled Trials as Topic ,Clinical Trials ,Phase II as Topic - Abstract
BACKGROUND: Economic incentives can improve clinical outcomes among in-care people living with HIV (PLHIV), but evidence is limited for their effectiveness among out-of-care PLHIV or those at risk of disengagement. We propose a type 1 hybrid effectiveness-implementation study to advance global knowledge about the use of economic incentives to strengthen the continuity of HIV care and accelerate global goals for HIV epidemic control. METHODS: The Rudi Kundini, Pamoja Kundini study will evaluate two implementation models of an economic incentive strategy for supporting two groups of PLHIV in Tanzania. Phase 1 of the study consists of a two-arm, cluster randomized trial across 32 health facilities to assess the effectiveness of a home visit plus one-time economic incentive on the proportion of out-of-care PLHIV with viral load suppression (
- Published
- 2024
30. Study protocol of a randomized controlled trial to assess the efficacy of the PrEPare for Work intervention to enhance PrEP uptake and optimize adherence for HIV prevention among male sex workers in the U.S.
- Author
-
Biello, Katie, Chan, Philip, Ndoye, Colleen, Nelson, Lance, Nelson, Elizabeth, Silva, Vanessa, Kwak, Eun, Napoleon, Siena, Cormack Orellana, Carolina, Richards, Olly, Davis, Evan, and Mimiaga, Matthew
- Subjects
Efficacy trial ,HIV infections ,Male sex work ,Motivational interviewing ,Pre-exposure prophylaxis ,Social cognitive theory ,Male ,Humans ,HIV Infections ,Homosexuality ,Male ,Sex Workers ,Sexual Behavior ,Counseling ,Pre-Exposure Prophylaxis ,Anti-HIV Agents ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND: Male sex workers (MSWs), specifically cisgender men who exchange sex for money, goods, drugs, or other items of value with other cisgender men, are at high risk for HIV infection. Compared to men not engaged in sex work, MSWs are more likely to engage in frequent condomless sex with paying and non-paying sexual partners. While MSWs are often included as a subgroup of gay and bisexual men, data show that a large proportion identify as heterosexual; additionally, most MSWs do not identify as sex workers. This places MSWs in a unique position where they may not engage with traditional HIV prevention programs, and when they do, they may not feel comfortable, leading to poor retention. Thus, HIV prevention interventions that address MSWs unique life circumstances and provide support in exploring their sexual health options are needed. METHODS: In this protocol paper, we describe the design and procedures for a National Institute of Health-funded, randomized controlled trial testing the efficacy of PrEPare for Work,- a theory-based, manualized PrEP uptake and adherence intervention for MSW - using a 2-stage randomization design. Stage 1: MSWs are equally randomized to receive either the PrEPare for Work Stage 1 intervention (strength-based case management and facilitated PrEP linkage) or Standard of Care (SOC) to evaluate successful PrEP uptake (prescription filled) within two months post-randomization. Stage 2: Those who initiate PrEP are then equally re-randomized to receive either the PrEPare for Work Stage 2 intervention (1-on-1 skills training, problem-solving, and motivational interviewing adherence counseling and personalized, daily text message reminders) or SOC to assess adherence (Tenofovir concentrations in hair) over 12 months of follow up. Planned analyses will examine intervention efficacy, specific conceptual mediators, and hypothesized moderators. DISCUSSION: Based on our extensive preliminary research, multi-component, theory-informed interventions targeting this subpopulation of MSWs unique life circumstances are urgently needed. In this study, we are evaluating whether PrEPare for Work can improve PrEP uptake and adherence among MSWs. If this intervention is efficacious, it would be readily disseminated to diverse community organizations that serve MSWs and possibly other community or clinic-based settings. TRIAL REGISTRATION: ClinicalTrials.gov number NCT05736614, registered February 8, 2023.
- Published
- 2024
31. Comparison of Effectiveness Among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials.
- Author
-
Kani, Ryoma, Watanabe, Atsuyuki, Miyamoto, Yoshihisa, Ejiri, Kentaro, Iwagami, Masao, Takagi, Hisato, Slipczuk, Leandro, Aikawa, Tadao, Kuno, Toshiki, and Tsugawa, Yusuke
- Subjects
CKD ,SGLT2 inhibitors ,cardiovascular death or hospitalizations for HF ,diabetes ,network meta‐analysis ,Humans ,Sodium-Glucose Transporter 2 Inhibitors ,Diabetes Mellitus ,Type 2 ,Glucose ,Network Meta-Analysis ,Randomized Controlled Trials as Topic ,Renal Insufficiency ,Chronic ,Heart Failure ,Acute Kidney Injury ,Benzhydryl Compounds ,Glucosides - Abstract
BACKGROUND: To investigate the individual profile of each SGLT2 (sodium-glucose cotransoporter-2) inhibitor in patients with different backgrounds. METHODS AND RESULTS: This study included 21 placebo-controlled randomized controlled trials with a total of 96 196 participants, investigating empagliflozin, ertugliflozin, dapagliflozin, canagliflozin, and sotagliflozin. The primary efficacy end point was the composite of cardiovascular death and hospitalizations for heart failure. The secondary efficacy end points were all-cause death, cardiovascular death, hospitalizations for heart failure, kidney disease progression, and acute kidney injury. We conducted subgroup analyses based on the underlying comorbidities, including diabetes and chronic kidney disease. Safety end points were also assessed among SGLT2 inhibitors in the overall cohort. In the overall cohort, there were no significant differences in the primary efficacy outcome among the SGLT2 inhibitors, while empagliflozin (hazard ratio [HR], 0.70 [95% CI, 0.53-0.92]) and dapagliflozin (HR, 0.73 [95% CI, 0.56-0.96]) were associated with lower risk of acute kidney injury than sotagliflozin. The presence or absence of diabetes did not alter the results. In patients with chronic kidney disease, there were no differences in the efficacy outcomes among SGLT2 inhibitors, while in patients without chronic kidney disease, empagliflozin was associated with lower risk of the primary outcome compared with ertugliflozin (HR, 0.77 [95% CI, 0.60-0.98]). For safety outcomes, no significant differences were observed in amputation, urinary tract infection, genital infection, hypoglycemia, and diabetic ketoacidosis. CONCLUSIONS: The differences in reducing cardiovascular and kidney outcomes as well as safety profiles across SGLT2 inhibitors were not consistently significant, although empagliflozin might be preferred in patients without chronic kidney disease. Further investigations are needed to better understand the mechanism and clinical effectiveness of each SGLT2 inhibitor in certain populations.
- Published
- 2024
32. Discontinuation and nonpublication of clinical trials in orthopaedic oncology.
- Author
-
Singh, Gurbinder, Wague, Aboubacar, Arora, Ayush, Rao, Varun, Ward, Derek, and Barry, Jeffrey
- Subjects
Clinical trials ,Discontinuation ,Enrollment size ,Intervention ,Nonpublication ,Orthopaedic oncology ,Humans ,Cross-Sectional Studies ,Orthopedics ,Pharmaceutical Preparations ,Publishing ,Randomized Controlled Trials as Topic ,Clinical Trials ,Phase III as Topic ,Clinical Trials ,Phase IV as Topic ,Medical Oncology - Abstract
BACKGROUND: Despite the pivotal role of clinical trials in advancing orthopaedic oncology knowledge and treatment strategies, the persistent issues of trial discontinuation and nonpublication are significant problems. This study conducted an analysis examining clinical trial discontinuation rates, associations between intervention types and discontinuation/nonpublication, and the role of funding, enrollment size, and their implications for trial success and completion. METHODS: This study, conducted on May 1, 2023, utilized a cross-sectional design to comprehensively analyze phase 3 and 4 randomized controlled trials within the realm of orthopaedic oncology. We specifically incorporated Phase 3 and 4 trials as they are designed to evaluate prolonged outcomes in human subjects and are more likely to reach publication. Study characteristics of interest included the intervention utilized in the clinical trial, presence of funding, whether the trial was published, completed, and trial enrollment size. The investigation involved an examination of ClinicalTrials.gov, a prominent online repository of clinical trial data managed by the National Library of Medicine of the USA. Descriptive statistics and multivariate logistic regressions were used to determine statistical significance. RESULTS: Among the cohort of 130 trials, 19.2% were prematurely discontinued. Completion rates varied based on intervention type; 111 pharmaceutical trials demonstrated a completion rate of 83.8%, whereas 19 non-pharmaceutical trials exhibited a completion rate of 8.0% (P
- Published
- 2024
33. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
- Author
-
Kappos, Ludwig, Traboulsee, Anthony, Li, David, Bar-Or, Amit, Barkhof, Frederik, Montalban, Xavier, Leppert, David, Baldinotti, Anna, Schneble, Hans-Martin, Koendgen, Harold, Sauter, Annette, Wang, Qing, and Hauser, Stephen
- Subjects
Disease-modifying therapies ,Multiple sclerosis ,Ocrelizumab ,Safety ,Humans ,Antibodies ,Monoclonal ,Humanized ,Immunologic Factors ,Interferon beta-1a ,Multiple Sclerosis ,Relapsing-Remitting ,Clinical Trials ,Phase II as Topic ,Randomized Controlled Trials as Topic - Abstract
Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase 2 trial on the longest follow-up to date of ocrelizumab-treated patients with relapsing-remitting MS (RRMS). The primary treatment period (PTP) comprised four 24-week treatment cycles; participants were randomized to double-blind ocrelizumab (2000 mg or 600 mg), placebo, or interferon β-1a (open label) for one cycle, then dose-blinded ocrelizumab 1000 mg or 600 mg for the remaining cycles. The PTP was followed by consecutive assessed and unassessed treatment-free periods (TFPs) and then the OLE (ocrelizumab 600 mg every 24 weeks). Safety and efficacy were prospectively assessed. Of 220 participants randomized, 183 (84%) completed the PTP. After the TFP, 103 entered OLE (median OLE ocrelizumab exposure 6.5 years). Most common adverse events across all periods were infusion-related reactions. MRI activity, annualized relapse rate, and confirmed disability progression (CDP) rates remained low throughout. During the assessed TFP, there was a trend toward less and later B-cell repletion, and later CDP, for patients randomized to ocrelizumab; MRI activity was observed in 16.3% of patients, the earliest 24 weeks after the last ocrelizumab dose. This is the longest follow-up of ocrelizumab-treated patients with RRMS, with no new safety signals emerging during an observation period from 2008 to 2020. Results reinforce the sustained efficacy of long-term ocrelizumab. Reduced disease activity was maintained following interruption of 6-month dosing cycles, with no evidence of rebound.
- Published
- 2024
34. Adaptive selection of the optimal strategy to improve precision and power in randomized trials
- Author
-
Balzer, Laura B, Cai, Erica, Garraza, Lucas Godoy, and Amaranath, Pracheta
- Subjects
Mathematical Sciences ,Statistics ,Clinical Research ,Clinical Trials and Supportive Activities ,Generic health relevance ,Good Health and Well Being ,United States ,Randomized Controlled Trials as Topic ,Linear Models ,Machine Learning ,Research Design ,Sample Size ,covariate adjustment ,efficiency ,machine learning ,pre-specification ,randomized trials ,TMLE ,Other Mathematical Sciences ,Statistics & Probability - Abstract
Benkeser et al. demonstrate how adjustment for baseline covariates in randomized trials can meaningfully improve precision for a variety of outcome types. Their findings build on a long history, starting in 1932 with R.A. Fisher and including more recent endorsements by the U.S. Food and Drug Administration and the European Medicines Agency. Here, we address an important practical consideration: how to select the adjustment approach-which variables and in which form-to maximize precision, while maintaining Type-I error control. Balzer et al. previously proposed Adaptive Pre-specification within TMLE to flexibly and automatically select, from a prespecified set, the approach that maximizes empirical efficiency in small trials (N < 40). To avoid overfitting with few randomized units, selection was previously limited to working generalized linear models, adjusting for a single covariate. Now, we tailor Adaptive Pre-specification to trials with many randomized units. Using V-fold cross-validation and the estimated influence curve-squared as the loss function, we select from an expanded set of candidates, including modern machine learning methods adjusting for multiple covariates. As assessed in simulations exploring a variety of data-generating processes, our approach maintains Type-I error control (under the null) and offers substantial gains in precision-equivalent to 20%-43% reductions in sample size for the same statistical power. When applied to real data from ACTG Study 175, we also see meaningful efficiency improvements overall and within subgroups.
- Published
- 2024
35. Impact of Intermittent Fasting and/or Caloric Restriction on Aging-Related Outcomes in Adults: A Scoping Review of Randomized Controlled Trials.
- Author
-
James, Dara, Hawley, Nanako, Mohr, Alex, Hermer, Janice, Ofori, Edward, Yu, Fang, and Sears, Dorothy
- Subjects
circadian rhythm ,dietary fasting ,energy restriction ,nightly fasting ,time-restricted eating ,Adult ,Humans ,Aging ,Caloric Restriction ,Cardiovascular Diseases ,Fasting ,Intermittent Fasting ,Neoplasms ,Randomized Controlled Trials as Topic - Abstract
Intermittent fasting (IF) and caloric restriction (CR) are dietary strategies to prevent and attenuate obesity associated with conditions and aging-related outcomes. This scoping review examined the cardiometabolic, cancer, and neurocognitive outcome differences between IF and CR interventions among adults. We applied a systematic approach to scope published randomized controlled trials (databases: PubMed, CINAHL Plus, PsychInfo, Scopus, and Google Scholar) from inception through August 2023. The initial search provided 389 unique articles which were critically appraised. Thirty articles met the eligibility criteria for inclusion: 12 were IF, 10 were CR, and 8 were combined IF and CR interventions. IF and CR were associated with weight loss; however, IF studies tended to report greater adherence compared with CR. Overall, IF and CR were equivalently effective across cardiometabolic, cancer, and neurocognitive outcomes. Our findings suggest that IF has health benefits in a variety of conditions and may be better accepted and tolerated than CR, but more comparative research is required.
- Published
- 2024
36. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
- Author
-
Northrup, Adam, Lewis, Sydney, Tam, Aaron, Carrillo, Carolina, Lewis, Robert, Matthews, Eva, Mendez, Blanca, Reyes, Letty, Rojas, Sarah, Ramers, Christian, Klaman, Stacey, and Godino, Job
- Subjects
Hepatitis C ,Hepatitis C treatment ,Linkage to care ,Mobile medical clinic ,People experiencing homelessness ,People who inject drugs ,Quality improvement ,Treatment initiation ,Adult ,Humans ,Hepacivirus ,Hepatitis C ,Chronic ,Substance Abuse ,Intravenous ,Drug Users ,Antiviral Agents ,Prospective Studies ,Quality Improvement ,Seroepidemiologic Studies ,Hepatitis C ,Algorithms ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND: As many as 2.4 million Americans are affected by chronic Hepatitis C Virus (HCV) in the United States.In 2018, the estimated number of adults with a history of HCV infection in San Diego County was 55,354 (95% CI: 25,411-93,329). This corresponded to a seroprevalence of 2.1% (95% CI: 2.1-3.4%). One-third of infections were among PWID. Published research has demonstrated that direct-acting antivirals (DAAs) have high efficacy and can now be used by primary care providers to treat HCV. In addition, limited evidence exists to support the effectiveness of simplified algorithms in clinical trial and real-world settings. Even with expanded access to HCV treatment in primary care settings, there are still groups, especially people who inject drugs (PWID) and people experiencing homelessness, who experience treatment disparities due to access and treatment barriers. The current study extends the simplified algorithm with a streetside one-stop-shop approach with integrated care (including the offer of buprenorphine prescriptions and abscess care) using a mobile clinic situated adjacent to a syringe service program serving many homeless populations. Rates of HCV treatment initiation and retention will be compared between patients offered HCV care in a mobile clinic adjacent to a syringe services program (SSP) and homeless encampment versus those who are linked to a community clinics current practice of usual care, which includes comprehensive patient navigation. METHODS: A quasi-experimental, prospective, interventional, comparative effectiveness trial with allocation of approximately 200 patients who inject drugs and have chronic HCV to the simplified care pathway (intervention group) or the usual care pathway (control group). Block randomization will be performed with a 1:1 randomization. DISCUSSION: Previous research has demonstrated acceptable outcomes for patients treated using simplified algorithms for DAAs and point-of-care testing in mobile medical clinics; however, there are opportunities to explore how these new, innovative systems of care impact treatment initiation rates or other HCV care cascade outcomes among PWID. TRIAL REGISTRATION: We have registered our study with ClinicalTrials.gov, a resource of the United States National Library of Medicine. This database contains research studies from United States and other countries around the world. Our study has not been previously published. The ClinicalTrials.gov registration identifier is NCT04741750.
- Published
- 2024
37. Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Trials.
- Author
-
Sreenivasan, Jayakumar, Reddy, Rohin, Jamil, Yasser, Malik, Aaqib, Chamie, Daniel, Howard, James, Nanna, Michael, Mintz, Gary, Maehara, Akiko, Ali, Ziad, Moses, Jeffrey, Chen, Shao-Liang, Chieffo, Alaide, Colombo, Antonio, Leon, Martin, Lansky, Alexandra, and Ahmad, Yousif
- Subjects
intravascular ultrasound ,meta‐analysis ,optical coherence tomography ,percutaneous coronary intervention ,Humans ,Coronary Artery Disease ,Coronary Angiography ,Percutaneous Coronary Intervention ,Ultrasonography ,Interventional ,Randomized Controlled Trials as Topic ,Thrombosis ,Treatment Outcome ,Death - Abstract
BACKGROUND: Despite the initial evidence supporting the utility of intravascular imaging to guide percutaneous coronary intervention (PCI), adoption remains low. Recent new trial data have become available. An updated study-level meta-analysis comparing intravascular imaging to angiography to guide PCI was performed. This study aimed to evaluate the clinical outcomes of intravascular imaging-guided PCI compared with angiography-guided PCI. METHODS AND RESULTS: A random-effects meta-analysis was performed on the basis of the intention-to-treat principle. The primary outcomes were major adverse cardiac events, cardiac death, and all-cause death. Mixed-effects meta-regression was performed to investigate the impact of complex PCI on the primary outcomes. A total of 16 trials with 7814 patients were included. The weighted mean follow-up duration was 28.8 months. Intravascular imaging led to a lower risk of major adverse cardiac events (relative risk [RR], 0.67 [95% CI, 0.55-0.82]; P
- Published
- 2024
38. The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) for serious mental illness in community mental health part 3: study protocol to evaluate sustainment in a hybrid type 2 effectiveness-implementation cluster-randomized trial.
- Author
-
Sarfan, Laurel, Agnew, Emma, Diaz, Marlen, Cogan, Ashby, Spencer, Julia, Esteva Hache, Rafael, Wiltsey Stirman, Shannon, Lewis, Cara, Kilbourne, Amy, and Harvey, Allison
- Subjects
Adaptation ,Circadian ,Community mental health ,Implementation ,Serious mental illness ,Sleep ,Sustainment ,Train-the-trainer ,TranS-C ,Transdiagnostic ,Humans ,Mental Health ,Sleep ,Surveys and Questionnaires ,Community Mental Health Centers ,Mental Disorders ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND: Although research on the implementation of evidence-based psychological treatments (EBPTs) has advanced rapidly, research on the sustainment of implemented EBPTs remains limited. This is concerning, given that EBPT activities and benefits regularly decline post-implementation. To advance research on sustainment, the present protocol focuses on the third and final phase-the Sustainment Phase-of a hybrid type 2 cluster-randomized controlled trial investigating the implementation and sustainment of the Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) for patients with serious mental illness and sleep and circadian problems in community mental health centers (CMHCs). Prior to the first two phases of the trial-the Implementation Phase and Train-the-Trainer Phase-TranS-C was adapted to fit the CMHC context. Then, 10 CMHCs were cluster-randomized to implement Standard or Adapted TranS-C via facilitation and train-the-trainer. The primary goal of the Sustainment Phase is to investigate whether adapting TranS-C to fit the CMHC context predicts improved sustainment outcomes. METHODS: Data collection for the Sustainment Phase will commence at least three months after implementation efforts in partnering CMHCs have ended and may continue for up to one year. CMHC providers will be recruited to complete surveys (N = 154) and a semi-structured interview (N = 40) on sustainment outcomes and mechanisms. Aim 1 is to report the sustainment outcomes of TranS-C. Aim 2 is to evaluate whether manipulating EBPT fit to context (i.e., Standard versus Adapted TranS-C) predicts sustainment outcomes. Aim 3 is to test whether provider perceptions of fit mediate the relation between treatment condition (i.e., Standard versus Adapted TranS-C) and sustainment outcomes. Mixed methods will be used to analyze the data. DISCUSSION: The present study seeks to advance our understanding of sustainment predictors, mechanisms, and outcomes by investigating (a) whether the implementation strategy of adapting an EBPT (i.e., TranS-C) to the CMHC context predicts improved sustainment outcomes and (b) whether this relation is mediated by improved provider perceptions of treatment fit. Together, the findings may help inform more precise implementation efforts that contribute to lasting change. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05956678 . Registered on July 21, 2023.
- Published
- 2024
39. Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial.
- Author
-
Rothrock, Robert, Ozair, Ahmad, Avendano, Maria, Herrera, Susana, Appel, Haley, Ramos, Suyen, Starosciak, Amy, Leon-Ariza, Daniel, Rubens, Muni, McDermott, Mike, Ahluwalia, Manmeet, Mehta, Minesh, and Kotecha, Rupesh
- Subjects
Bone metastasis ,External beam radiotherapy ,Prophylactic radiation ,Skeletal-related event ,Spine lesion ,Vertebral fracture ,Vertebral metastasis ,Adult ,Humans ,Spine ,Spinal Fractures ,Spinal Neoplasms ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND: Early palliative/pre-emptive intervention improves clinical outcomes and quality of life for patients with metastatic cancer. A previous signal-seeking randomized controlled trial (RCT) demonstrated that early upfront radiotherapy to asymptomatic or minimally symptomatic high-risk osseous metastases led to reduction in skeletal-related events (SREs), a benefit driven primarily by subgroup of high-risk spine metastasis. The current RCT aims to determine whether early palliative/pre-emptive radiotherapy in patients with high-risk, asymptomatic or minimally symptomatic spine metastases will lead to fewer SREs within 1 year. METHODS: This is a single-center, parallel-arm, in-progress RCT in adults (≥ 18 years) with ECOG performance status 0-2 and asymptomatic or minimally symptomatic (not requiring opioids) high-risk spine metastases from histologically confirmed solid tumor malignancies with > 5 sites of metastatic disease on cross-sectional imaging. High-risk spine metastases are defined by the following: (a) bulkiest disease sites ≥ 2 cm; (b) junctional disease (occiput to C2, C7-T1, T12-L2, L5-S1); (c) posterior element involvement; or (d) vertebral body compression deformity > 50%. Patients are randomized 1:1 to receive either standard-of-care systemic therapy (arm 1) or upfront, early radiotherapy to ≤ 5 high-risk spine lesions plus standard-of-care systemic therapy (arm 2), in the form of 20-30 Gy of radiation in 2-10 fractions. The primary endpoint is SRE, a composite outcome including spinal fracture, spinal cord compression, need for palliative radiotherapy, interventional procedures, or spinal surgery. Secondary endpoints include (1) surrogates of health care cost, including the number and duration of SRE-related hospitalizations; (2) overall survival; (3) pain-free survival; and (4) quality of life. Study instruments will be captured pre-treatment, at baseline, during treatment, and at 1, 3, 6, 12, and 24 months post-treatment. The trial aims to accrue 74 patients over 2 years to achieve > 80% power in detecting difference using two-sample proportion test with alpha
- Published
- 2024
40. A multilevel intervention to promote HPV vaccination among young adults in Texas: protocol for a randomized controlled trial
- Author
-
Lu, Qian, Dawkins-Moultin, Lenna, Cho, Dalnim, Tan, Naomi QP, Hopfer, Suellen, Li, Yisheng, Ramondetta, Lois, Xu, Yusi, Lun, Di, and Chen, Minxing
- Subjects
Epidemiology ,Health Services and Systems ,Public Health ,Health Sciences ,Infectious Diseases ,Cervical Cancer ,Clinical Trials and Supportive Activities ,Prevention ,Pediatric ,Cancer ,Immunization ,Sexually Transmitted Infections ,HPV and/or Cervical Cancer Vaccines ,Vaccine Related ,Women's Health ,Clinical Research ,Urologic Diseases ,3.4 Vaccines ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Adolescent ,Adult ,Female ,Humans ,Male ,Young Adult ,Health Promotion ,Papillomavirus Infections ,Papillomavirus Vaccines ,Texas ,Vaccination ,Randomized Controlled Trials as Topic ,Papillomavirus vaccines ,Young adults ,Narrative persuasion ,Randomized controlled trial ,Multilevel intervention ,Psychosocial intervention ,Video narratives ,Written narratives ,Access ,Version 1. ,Public Health and Health Services ,Health services and systems ,Public health - Abstract
BackgroundHuman papillomavirus (HPV) infections can cause cancers of the cervix, vagina, vulva, penis, anus, and oropharynx. The most recently approved HPV vaccine, Gardasil-9, protects against HPV infection and can prevent HPV-associated invasive cancers. However, Gardasil-9 is one of the most underused vaccines in the US today. Young adults are at risk for HPV infection, but many are not vaccinated. This study uses a randomized controlled trial (RCT) to test an innovative multilevel intervention to increase HPV vaccination rates among young adults. In this paper, we describe the research protocol.MethodsThe study uses a two by three factorial design. A total of 1200 young adults in Texas, age 18-26 years, who have not been previously fully vaccinated against HPV will be randomly assigned to one of six conditions to receive: (1) standard CDC information about HPV vaccination (control); (2) video narratives about HPV vaccination; (3) written narratives about HPV vaccination; or (4-6) enhanced access to HPV vaccine combined with (4) standard CDC information, (5) video narratives, or (6) written narratives. The two primary outcomes are the rate of HPV vaccination initiation by 3-month follow-up and rate of HPV vaccination completion by 9-month follow-ups. We will determine the impact of the individual level intervention (i.e., persuasive narratives through video or written format), the systemic level intervention (i.e., enhanced access to HPV vaccines), and the combination of both levels, on HPV vaccination initiation and completion. We will also use purposive sampling to select participants to take part in semi-structured interviews/focus groups to better understand the mechanisms of the intervention.DiscussionRecruitment and data collection began in March 2022. We expect to complete data collection by March 2026. We expect that narratives, enhanced access, and the combination of both will improve HPV vaccination initiation and completion rates among young adults. If proven successful, these individual- and system-level interventions can be easily disseminated in regions with low HPV vaccination rates to improve HPV vaccination, and ultimately decrease HPV-related cancer burden.Trial registrationNCT05057312.
- Published
- 2024
41. Study Protocol for a Cluster, Randomized, Controlled Community Effectiveness Trial of the Early Start Denver Model (ESDM) Compared to Community Early Behavioral Intervention (EBI) in Community Programs serving Young Autistic Children: Partnering for Autism: Learning more to improve Services (PALMS)
- Author
-
Stahmer, Aubyn C, Dufek, Sarah, Rogers, Sally J, and Iosif, Ana-Maria
- Subjects
Biological Psychology ,Clinical and Health Psychology ,Psychology ,Applied and Developmental Psychology ,Social Determinants of Health ,Clinical Research ,Comparative Effectiveness Research ,Clinical Trials and Supportive Activities ,Brain Disorders ,Dissemination and Implementation Research ,Intellectual and Developmental Disabilities (IDD) ,Behavioral and Social Science ,Minority Health ,Mental Health ,Autism ,Pediatric ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Humans ,Child ,Preschool ,Behavior Therapy ,Autistic Disorder ,Early Intervention ,Educational ,Female ,Male ,Infant ,Randomized Controlled Trials as Topic ,Early intervention ,Early start Denver model ,NDBI ,Community implementation ,Applied and developmental psychology ,Biological psychology ,Clinical and health psychology - Abstract
BackgroundThe rising number of children identified with autism has led to exponential growth in for-profit applied behavior analysis (ABA) agencies and the use of highly structured approaches that may not be developmentally appropriate for young children. Multiple clinical trials support naturalistic developmental behavior interventions (NDBIs) that integrate ABA and developmental science and are considered best practices for young autistic children. The Early Start Denver Model (ESDM) is a comprehensive NDBI shown to improve social communication outcomes for young autistic children in several controlled efficacy studies. However, effectiveness data regarding NDBI use in community-based agencies are limited.MethodsThis study uses a community-partnered approach to test the effectiveness of ESDM compared to usual early behavioral intervention (EBI) for improving social communication and language in autistic children served by community agencies. This is a hybrid type 1 cluster-randomized controlled trial with 2 conditions: ESDM and EBI. In the intervention group, supervising providers will receive training in ESDM; in the control group, they will continue EBI as usual. We will enroll and randomize 100 supervisors (50 ESDM, 50 EBI) by region. Each supervisor enrolls 3 families of autistic children under age 5 (n = 300) and accompanying behavior technicians (n = 200). The primary outcome is child language and social communication at 6 and 12 months. Secondary outcomes include child adaptive behavior, caregiver use of ESDM strategies, and provider intervention fidelity. Child social motivation and caregiver fidelity will be tested as mediating variables. ESDM implementation determinants will be explored using mixed methods.DiscussionThis study will contribute novel knowledge on ESDM effectiveness, the variables that mediate and moderate child outcomes, and engagement of its mechanisms in community use. We expect results from this trial to increase community availability of this model and access to high-quality intervention for young autistic children, especially those who depend on publicly funded intervention services. Understanding implementation determinants will aid scale-up of effective models within communities.Trail registrationClinicaltrials.gov identifier number NCT06005285. Registered on August 21, 2023.Protocol versionIssue date 6 August 2024; Protocol amendment number: 02.
- Published
- 2024
42. Remote ischemic conditioning may improve graft function following kidney transplantation: a systematic review and meta-analysis with trial sequential analysis
- Author
-
Zhang, Yang, Long, Yuqin, Li, Yongjun, Liao, Dawei, Hu, Linkun, Peng, Ke, Liu, Hong, Ji, Fuhai, and Shan, Xisheng
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Transplantation ,Clinical Research ,Organ Transplantation ,Clinical Trials and Supportive Activities ,Kidney Disease ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Renal and urogenital ,Humans ,Kidney Transplantation ,Ischemic Preconditioning ,Delayed Graft Function ,Randomized Controlled Trials as Topic ,Graft Rejection ,Remote ischemic conditioning ,Kidney transplantation ,Graft function ,Systematic review ,Medical Physiology ,Anesthesiology ,Clinical sciences - Abstract
BackgroundRemote ischemic conditioning (RIC) has the potential to benefit graft function following kidney transplantation by reducing ischemia-reperfusion injury; however, the current clinical evidence is inconclusive. This meta-analysis with trial sequential analysis (TSA) aimed to determine whether RIC improves graft function after kidney transplantation.MethodsA comprehensive search was conducted on PubMed, Cochrane Library, and EMBASE databases until June 20, 2023, to identify all randomized controlled trials that examined the impact of RIC on graft function after kidney transplantation. The primary outcome was the incidence of delayed graft function (DGF) post-kidney transplantation. The secondary outcomes included the incidence of acute rejection, graft loss, 3- and 12-month estimated glomerular filtration rates (eGFR), and the length of hospital stay. Subgroup analyses were conducted based on RIC procedures (preconditioning, perconditioning, or postconditioning), implementation sites (upper or lower extremity), and graft source (living or deceased donor).ResultsOur meta-analysis included eight trials involving 1038 patients. Compared with the control, RIC did not significantly reduce the incidence of DGF (8.8% vs. 15.3%; risk ratio = 0.76, 95% confidence interval [CI], 0.48-1.21, P = 0.25, I2 = 16%), and TSA results showed that the required information size was not reached. However, the RIC group had a significantly increased eGFR at 3 months after transplantation (mean difference = 2.74 ml/min/1.73 m2, 95% CI: 1.44-4.05 ml/min/1.73 m2, P
- Published
- 2024
43. Social network tie functions of social support and social influence and adult smoking abstinence.
- Author
-
Zheng, Yu, Lakon, Cynthia, and Pechmann, Cornelia
- Subjects
Adult ,Humans ,Health Behavior ,Smoking ,Smoking Cessation ,Social Networking ,Social Support ,Randomized Controlled Trials as Topic - Abstract
Adults social network ties serve multiple functions and play prominently in quitting smoking. We examined three types of adults egocentric social networks, including family, friends, and friends online to investigate how two network characteristics with major relevance to health behavior, network size and tie closeness, related to the emotional and confidant support and to pro- and anti-smoking social influence these ties may transmit. We also examine whether the social support and social influence constructs related to smoking abstinence. We utilized baseline and 7-day abstinence survey data from 123 adult current smokers attempting to quit prior to the start of a randomized controlled quit-smoking trial of a social support intervention for quitting smoking on Twitter. To examine study relationships, we estimated Negative Binomial Regression models and Logistic Regression models. For all networks, network size and tie closeness related positively to most of the social support and social influence constructs, with tie closeness related most strongly, especially for online friends. Family pro-smoking social influence related negatively to smoking abstinence, and there were marginally negative relationships for family emotional support and family confidant support. Online friend emotional support had a marginally positive relationship with smoking abstinence. Overall, our findings indicated the importance of the social support and social influence functions of each type of network tie, with larger networks and closer ties related to higher levels of social support and social influence. Moreover, family network pro-smoking social influence may compromise abstinence while emotional support from online friend network ties may reinforce it.
- Published
- 2024
44. Autism Caregiver Coaching in Africa (ACACIA): Protocol for a type 1-hybrid effectiveness-implementation trial
- Author
-
Franz, Lauren, Viljoen, Marisa, Askew, Sandy, Brown, Musaddiqah, Dawson, Geraldine, Di Martino, J Matias, Sapiro, Guillermo, Sebolai, Katlego, Seris, Noleen, Shabalala, Nokuthula, Stahmer, Aubyn, Turner, Elizabeth L, and de Vries, Petrus J
- Subjects
Health Services and Systems ,Health Sciences ,Clinical Research ,Autism ,Intellectual and Developmental Disabilities (IDD) ,Prevention ,Behavioral and Social Science ,Brain Disorders ,Clinical Trials and Supportive Activities ,Pediatric ,Mental Health ,Quality Education ,Child ,Child ,Preschool ,Humans ,Acacia ,Autistic Disorder ,Caregivers ,Mentoring ,Randomized Controlled Trials as Topic ,South Africa ,Infant ,General Science & Technology - Abstract
BackgroundWhile early autism intervention can significantly improve outcomes, gaps in implementation exist globally. These gaps are clearest in Africa, where forty percent of the world's children will live by 2050. Task-sharing early intervention to non-specialists is a key implementation strategy, given the lack of specialists in Africa. Naturalistic Developmental Behavioral Interventions (NDBI) are a class of early autism intervention that can be delivered by caregivers. As a foundational step to address the early autism intervention gap, we adapted a non-specialist delivered caregiver coaching NDBI for the South African context, and pre-piloted this cascaded task-sharing approach in an existing system of care.ObjectivesFirst, we will test the effectiveness of the caregiver coaching NDBI compared to usual care. Second, we will describe coaching implementation factors within the Western Cape Department of Education in South Africa.MethodsThis is a type 1 effectiveness-implementation hybrid design; assessor-blinded, group randomized controlled trial. Participants include 150 autistic children (18-72 months) and their caregivers who live in Cape Town, South Africa, and those involved in intervention implementation. Early Childhood Development practitioners, employed by the Department of Education, will deliver 12, one hour, coaching sessions to the intervention group. The control group will receive usual care. Distal co-primary outcomes include the Communication Domain Standard Score (Vineland Adaptive Behavior Scales, Third Edition) and the Language and Communication Developmental Quotient (Griffiths Scales of Child Development, Third Edition). Proximal secondary outcome include caregiver strategies measured by the sum of five items from the Joint Engagement Rating Inventory. We will describe key implementation determinants.ResultsParticipant enrolment started in April 2023. Estimated primary completion date is March 2027.ConclusionThe ACACIA trial will determine whether a cascaded task-sharing intervention delivered in an educational setting leads to meaningful improvements in communication abilities of autistic children, and identify implementation barriers and facilitators.Trial registrationNCT05551728 in Clinical Trial Registry (https://clinicaltrials.gov).
- Published
- 2024
45. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study)
- Author
-
Goodman-Meza, David, Shoptaw, Steven, Hanscom, Brett, Smith, Laramie R, Andrew, Philip, Kuo, Irene, Lake, Jordan E, Metzger, David, Morrison, Ellen AB, Cummings, Melissa, Fogel, Jessica M, Richardson, Paul, Harris, Jayla, Heitner, Jesse, Stansfield, Sarah, and El-Bassel, Nabila
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Clinical Sciences ,Social Determinants of Health ,Brain Disorders ,Minority Health ,Sexually Transmitted Infections ,Health Disparities ,Comparative Effectiveness Research ,Behavioral and Social Science ,Infectious Diseases ,Clinical Trials and Supportive Activities ,Opioid Misuse and Addiction ,Substance Misuse ,Clinical Research ,Prevention ,Women's Health ,HIV/AIDS ,Health Services ,Drug Abuse (NIDA only) ,Opioids ,6.6 Psychological and behavioural ,8.1 Organisation and delivery of services ,Infection ,Mental health ,Good Health and Well Being ,Humans ,Pharmaceutical Preparations ,Substance Abuse ,Intravenous ,Drug Users ,HIV Infections ,Sexually Transmitted Diseases ,Opioid-Related Disorders ,Randomized Controlled Trials as Topic ,HPTN 094 Study Team ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,General & Internal Medicine ,Clinical sciences ,Epidemiology ,Health services and systems - Abstract
BackgroundPersons with opioid use disorders who inject drugs (PWID) in the United States (US) face multiple and intertwining health risks. These include interference with consistent access, linkage, and retention to health care including medication for opioid use disorder (MOUD), HIV prevention using pre-exposure prophylaxis (PrEP), and testing and treatment for sexually transmitted infections (STIs). Most services, when available, including those that address substance misuse, HIV prevention, and STIs, are often provided in multiple locations that may be difficult to access, which further challenges sustained health for PWID. HPTN 094 (INTEGRA) is a study designed to test the efficacy of an integrated, "whole-person" strategy that provides integrated HIV prevention including antiretroviral therapy (ART), PrEP, MOUD, and STI testing and treatment from a mobile health delivery unit ("mobile unit") with peer navigation compared to peer navigation alone to access these services at brick and mortar locations.MethodsHPTN 094 (INTEGRA) is a two-arm, randomized controlled trial in 5 US cities where approximately 400 PWID without HIV are assigned either to an experimental condition that delivers 26 weeks of "one-stop" integrated health services combined with peer navigation and delivered in a mobile unit or to an active control condition using peer navigation only for 26 weeks to the same set of services delivered in community settings. The primary outcomes include being alive and retained in MOUD and PrEP at 26 weeks post-randomization. Secondary outcomes measure the durability of intervention effects at 52 weeks following randomization.DiscussionThis trial responds to a need for evidence on using a "whole-person" strategy for delivering integrated HIV prevention and substance use treatment, while testing the use of a mobile unit that meets out-of-treatment PWID wherever they might be and links them to care systems and/or harm reduction services. Findings will be important in guiding policy for engaging PWID in HIV prevention or care, substance use treatment, and STI testing and treatment by addressing the intertwined epidemics of addiction and HIV among those who have many physical and geographic barriers to access care.Trial registrationClinicalTrials.gov NCT04804072 . Registered on 18 March 2021.
- Published
- 2024
46. Food Insecurity and Engagement in Transactional Sex Among Female Secondary Students in Rwanda.
- Author
-
Izudi, Jonathan, Gatare, Emmyson, Packel, Laura, Kayitesi, Laetitia, Sayinzoga, Felix, Hope, Rebecca, McCoy, Sandra, and Sheira, Lila
- Subjects
Adolescent girls ,Food security ,Rwanda ,Transactional sex ,Young women ,Adolescent ,Child ,Female ,Humans ,Young Adult ,Cross-Sectional Studies ,Food Insecurity ,Food Supply ,HIV Infections ,Randomized Controlled Trials as Topic ,Rwanda ,Sexual Behavior ,Students - Abstract
The relationship between food insecurity and transactional sex is well recognized, but less is known about this relationship among adolescents. We analyzed cross-sectional baseline data from 3,130 female secondary students aged 12-19 enrolled in a three-arm, cluster randomized controlled trial to examine the association between food insecurity and transactional sex. The explanatory variable was food security and the outcome was ever engaging in transactional sex. Over one quarter (28.7%) reported any food insecurity and 1.9% of all participants (9.6% of sexually active participants) reported ever engaging in transactional sex. In adjusted models, ever experiencing any food insecurity was associated with a higher prevalence of ever transactional sex (PR: 1.60; 95% CI: 1.02, 2.49) compared to little to no food insecurity. These results provide insight into potential predictors of higher-risk sexual behavior in Rwanda; they also provide policy-makers with populations with whom to intervene on upstream determinants of transactional sex, notably poverty and food insecurity.
- Published
- 2024
47. Multiple sclerosis: time for early treatment with high-efficacy drugs.
- Author
-
Barnett, Michael, Thompson, Alan, Hartung, Hans-Peter, Selmaj, Krzysztof, and Cree, Bruce
- Subjects
Escalation therapy ,High-efficacy drugs ,Multiple sclerosis ,Safety ,Humans ,Multiple Sclerosis ,Pharmaceutical Preparations ,Treatment Outcome ,Multiple Sclerosis ,Relapsing-Remitting ,Randomized Controlled Trials as Topic - Abstract
This review addresses current changes in the approach to treating patients with multiple sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment efficacy (LETA) at onset with subsequent escalation has been challenged by new data suggesting that MS patients derive greater benefit when therapy is initiated with high-efficacy treatment agents (HETA). Several recent studies compared treatment efficacy and safety of early administration of HETA versus LETA. The results of randomized, double blind, phase III studies with LETA as a control arm and population-based larger and longer studies using propensity scoring, marginal structural modeling and weighted cumulative exposure analysis support the benefit of early treatment with HETA. Patients initiating their treatment with HETA, regardless of prognostic factors and MRI burden at baseline, showed significantly lower annualized relapse rate (ARR) and reduced disability progression in follow-up periods of up to 10-15 years. Moreover, the safety profile of recently approved HETA ameliorates concerns about off-target effects associated with a number of earlier high-efficacy drugs. Patient perception has also changed with an increasing preference for medication profiles that both improve symptoms and prevent disease progression. Accumulating data from randomized studies and the results of large population-based studies demonstrating short-term and longer-term patient benefits support the view that HETA should be more widely used. The adoption of early treatment with HETA capitalizes on a window of opportunity for anti-inflammatory drugs to maximally impact disease pathology and heralds a sea change in clinical practice toward pro-active management and away from a philosophy routed in generating clinical benefit as a consequence of treatment failure.
- Published
- 2024
48. Effectiveness of comprehensive geriatric assessment adapted to primary care when provided by a nurse or a general practitioner: the CEpiA cluster-randomised trial.
- Author
-
Orcel, Veronique, Banh, Leon, Bastuji-Garin, Sylvie, Renard, Vincent, Boutin, Emmanuelle, Gouja, Amel, Caillet, Philippe, Paillaud, Elena, Audureau, Etienne, and Ferrat, Emilie
- Subjects
- *
EMERGENCY room visits , *QUALITY of life , *ACTIVITIES of daily living , *PRIMARY care , *GERIATRIC assessment - Abstract
Background: The benefits of comprehensive geriatric assessment (CGA) are well established for hospital care but less so for primary care. Our primary objective was to assess the effect of two multifaceted interventions based on a CGA adapted for primary care on a composite criterion combining all-cause mortality, emergency department visits, unplanned hospital admissions, and institutionalisation. Methods: This open-label, pragmatic, three-arm, cluster-randomised controlled trial involved 39 general practices in France. It included 634 patients aged 70 years or over with chronic health conditions and/or an unplanned hospital admission in the past 3 months, between 05/2016 and 08/2018. Interventions were in arm 1: a systematic nurse-led CGA; arm 2: a GP-led CGA, at the GP's discretion; arm 3: standard care. The primary composite endpoint was assessed at 12 months. The secondary endpoints included: components of the composite endpoint, health-related quality of life (Duke Health Profile), functional status (Katz Activities of Daily Living Index) and medications (number) at 12 months. Pairwise comparisons between the experimental groups and the control were tested. The main analysis was performed on the intention-to-treat (ITT) population, after imputing missing information and adjusting for baseline imbalances by mixed effects regressions. Results: For the primary composite outcome, no statistically significant difference was found between arm 1 and the control (adjusted odds ratio [aOR] = 0.81 [95%CI 0.54–1.21], P = 0.31), whereas arm 2 and the control differed significantly (aOR = 0.60 [0.39–0.93], P = 0.022). A statistically lower risk of unplanned hospital admission in arm 2 vs control (aOR = 0.57 [0.36–0.92], P = 0.020)) was observed, while no statistically significant differences were found for the other components and between arm 1 and the control. None of the other secondary endpoints differed between arms. Conclusions: Our study led in community-dwelling older patients with chronic conditions found no significant effect of a CGA adapted for primary care on mortality, functional independence and quality of life, but suggests that a GP-led CGA may reduce the risk of unplanned hospital admission. Our study demonstrates the feasibility of incorporating CGA into clinical practice and highlights its potential benefits when applied on a case-by-case basis, guided by the GPs who develop the resulting PCP. Trial registration: NCT02664454. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Cesena guidelines: WSES consensus statement on laparoscopic-first approach to general surgery emergencies and abdominal trauma.
- Author
-
Sermonesi, Giacomo, Tian, Brian, Vallicelli, Carlo, Abu-Zidan, Fikri, Damaskos, Dimitris, Kelly, Michael, Leppäniemi, Ari, Galante, Joseph, Tan, Edward, Kirkpatrick, Andrew, Khokha, Vladimir, Romeo, Oreste, Chirica, Mircea, Pikoulis, Manos, Litvin, Andrey, Shelat, Vishal, Sakakushev, Boris, Wani, Imtiaz, Sall, Ibrahima, Fugazzola, Paola, Cicuttin, Enrico, Toro, Adriana, Amico, Francesco, Mas, Francesca, De Simone, Belinda, Sugrue, Michael, Bonavina, Luigi, Campanelli, Giampiero, Carcoforo, Paolo, Cobianchi, Lorenzo, Coccolini, Federico, Chiarugi, Massimo, Di Carlo, Isidoro, Di Saverio, Salomone, Podda, Mauro, Pisano, Michele, Sartelli, Massimo, Testini, Mario, Fette, Andreas, Rizoli, Sandro, Picetti, Edoardo, Weber, Dieter, Latifi, Rifat, Kluger, Yoram, Balogh, Zsolt, Biffl, Walter, Jeekel, Hans, Civil, Ian, Hecker, Andreas, Ansaloni, Luca, Bravi, Francesca, Agnoletti, Vanni, Beka, Solomon, Moore, Ernest, and Catena, Fausto
- Subjects
Acute appendicitis ,Acute care surgery ,Acute cholecystitis ,Acute diverticulitis ,Acute pancreatitis ,Acute peritonitis ,Adhesive small bowel obstruction ,Colo–rectal emergencies ,Emergency general surgery ,Guidelines ,Incarcerated/complicated ventral/inguinal hernia ,Laparoscopic approach ,Laparoscopy ,Mesenteric ischemia ,Minimally invasive surgery/approach ,Penetrating/blunt abdominal trauma ,Perforated peptic ulcer ,Recommendations ,Trauma surgery hemodynamic stability ,Humans ,Emergencies ,Retrospective Studies ,Laparoscopy ,Abdomen ,Abdominal Injuries ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND: Laparoscopy is widely adopted across nearly all surgical subspecialties in the elective setting. Initially finding indication in minor abdominal emergencies, it has gradually become the standard approach in the majority of elective general surgery procedures. Despite many technological advances and increasing acceptance, the laparoscopic approach remains underutilized in emergency general surgery and in abdominal trauma. Emergency laparotomy continues to carry a high morbidity and mortality. In recent years, there has been a growing interest from emergency and trauma surgeons in adopting minimally invasive surgery approaches in the acute surgical setting. The present position paper, supported by the World Society of Emergency Surgery (WSES), aims to provide a review of the literature to reach a consensus on the indications and benefits of a laparoscopic-first approach in patients requiring emergency abdominal surgery for general surgery emergencies or abdominal trauma. METHODS: This position paper was developed according to the WSES methodology. A steering committee performed the literature review and drafted the position paper. An international panel of 54 experts then critically revised the manuscript and discussed it in detail, to develop a consensus on a position statement. RESULTS: A total of 323 studies (systematic review and meta-analysis, randomized clinical trial, retrospective comparative cohort studies, case series) have been selected from an initial pool of 7409 studies. Evidence demonstrates several benefits of the laparoscopic approach in stable patients undergoing emergency abdominal surgery for general surgical emergencies or abdominal trauma. The selection of a stable patient seems to be of paramount importance for a safe adoption of a laparoscopic approach. In hemodynamically stable patients, the laparoscopic approach was found to be safe, feasible and effective as a therapeutic tool or helpful to identify further management steps and needs, resulting in improved outcomes, regardless of conversion. Appropriate patient selection, surgeon experience and rigorous minimally invasive surgical training, remain crucial factors to increase the adoption of laparoscopy in emergency general surgery and abdominal trauma. CONCLUSIONS: The WSES expert panel suggests laparoscopy as the first approach for stable patients undergoing emergency abdominal surgery for general surgery emergencies and abdominal trauma.
- Published
- 2023
50. Efficacy and Adherence Rates of a Novel Community-Informed Virtual World-Based Cardiac Rehabilitation Program: Protocol for the Destination Cardiac Rehab Randomized Controlled Trial.
- Author
-
Brewer, LaPrincess, Abraham, Helayna, Clark, Donald, Echols, Melvin, Hall, Michael, Hodgman, Karen, Kaihoi, Brian, Kopecky, Stephen, Krogman, Ashton, Leth, Shawn, Marsteller, Jill, Mathews, Lena, Scales, Robert, Schulte, Phillip, Shultz, Adam, Taylor, Bryan, Thomas, Randal, Olson, Thomas, Malik, Shaista, and Wong, Nathan
- Subjects
cardiac rehabilitation ,cardiovascular health ,health disparities ,home‐based programs ,social determinants of health ,Humans ,Cardiac Rehabilitation ,Telerehabilitation ,Exercise ,Randomized Controlled Trials as Topic - Abstract
BACKGROUND: Innovative restructuring of cardiac rehabilitation (CR) delivery remains critical to reduce barriers and improve access to diverse populations. Destination Cardiac Rehab is a novel virtual world technology-based CR program delivered through the virtual world platform, Second Life, which previously demonstrated high acceptability as an extension of traditional center-based CR. This study aims to evaluate efficacy and adherence of the virtual world-based CR program compared with center-based CR within a community-informed, implementation science framework. METHODS: Using a noninferiority, hybrid type 1 effectiveness-implementation, randomized controlled trial, 150 patients with an eligible cardiovascular event will be recruited from 6 geographically diverse CR centers across the United States. Participants will be randomized 1:1 to either the 12-week Destination Cardiac Rehab or the center-based CR control groups. The primary efficacy outcome is a composite cardiovascular health score based on the American Heart Association Lifes Essential 8 at 3 and 6 months. Adherence outcomes include CR session attendance and participation in exercise sessions. A diverse patient/caregiver/stakeholder advisory board was assembled to guide recruitment, implementation, and dissemination plans and to contextualize study findings. The institutional review board-approved randomized controlled trial will enroll and randomize patients to the intervention (or control group) in 3 consecutive waves/year over 3 years. The results will be published at data collection and analyses completion. CONCLUSIONS: The Destination Cardiac Rehab randomized controlled trial tests an innovative and potentially scalable model to enhance CR participation and advance health equity. Our findings will inform the use of effective virtual CR programs to expand equitable access to diverse patient populations. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05897710.
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.